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THE ROLE OF YES-ASSOCIATED PROTEIN 1 IN  
OVARIAN PHYSIOLOGY AND PATHOLOGY 
Xiangmin Lv, Ph.D. 
University of Nebraska, 2017 
Supervisor: Cheng Wang, Ph.D. 
Ovarian granulosa cells are the major somatic components of the ovarian follicle. 
Proper proliferation and differentiation of ovarian granulosa cells are essential for 
successful follicle development. Accumulating evidence indicates that the Hippo-YAP 
signaling pathway plays critical roles in both development and tumorigenesis of several 
organs. The present study aims to investigate the role of Yes-associated protein 1 (YAP) 
in ovarian granulosa cell proliferation, differentiation, and malignant transformation. At 
first, we found that nuclear YAP (active) was highly expressed in proliferative granulosa 
cells, whereas cytoplasmic YAP (inactive) was detected mainly in terminally-differentiated 
luteal cells. Further studies suggested that endogenous YAP activity is essential for 
granulosa cell proliferation and survival to support follicle growth. However, overactive 
YAP impaired differentiation and stimulated malignant transformation of granulosa cells, 
indicating that YAP overactivation may play a role in the development of granulosa cell 
tumors which come from failure of terminal differentiation of granulosa cells to luteal cells. 
This idea was further supported by the overexpression of YAP detected in the human 
granulosa cell tumor tissues and the critical role of YAP in the progression of granulosa 
cell tumor. 
High-grade serous ovarian cancer (HGSOC) is the most common and lethal type of 
ovarian cancer. A novel mesenchymal subtype of HGSOC has been recently identified by 
iv 
both The Cancer Genome Atlas and Australian Ovarian Cancer Study studies and the 
origin of this subtype has yet to be defined. Here, my studies show that YAP can induce 
high-grade ovarian cancers with mesenchymal features from poorly differentiated 
granulosa cells. In xenograft mouse models, overactive YAP elicits malignant ovarian 
cancer development in the peritoneum of host mice from poorly differentiated human 
granulosa cells. These tumors presented in mouse peritoneum as typical human HGSOC 
morphologically, histologically, and genetically. However, these tumors overexpressed N-
cadherin and vimentin but had low expression of CA125 and E-cadherin, features 
reminiscent of the recently identified mesenchymal HGSOC. These studies suggest that 
granulosa cells may be a cell-of-origin for the mesenchymal type of HGSOC.  
v 
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CHAPTER 1: YAP REGULATES PHYSIOLOGY OF GRANULOSA CELLS* 
  
                                               
* The material presented in this chapter was submitted as a manuscript: Lv et al. 2017. 
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ABSTRACT 
Ovarian granulosa cells are the major somatic components of the ovarian follicle, and 
proper granulosa cell proliferation and differentiation are critical for normal follicle 
development. Recent studies suggest that the Hippo-YAP pathway controls the 
development of several organs; however, its role in ovarian follicle development remains 
largely unknown. The present study investigates the role of YAP in ovarian granulosa cell 
physiology. Immunohistochemical analyses showed that nuclear YAP was highly 
expressed in proliferative granulosa cells, whereas cytoplasmic YAP was mainly detected 
in terminally differentiated luteal cells, indicating that YAP activity may be involved in the 
regulation of proliferation and differentiation of ovarian granulosa cells. YAP inhibition by 
siRNA or pharmacological antagonist in human granulosa cells suppressed cell 
proliferation, and overexpression of wild-type or constitutively active YAP impaired 
gonadotropin-induced differentiation and stimulated rapid proliferation and malignant 
transformation of granulosa cells. Cell signaling studies suggested that HBEGF, which 
upregulated by YAP, activated YAP and promoted proliferation of granulosa cells. 
Conversely, gonadotropin-activated PKA signaling inhibited YAP activity and stimulated 
differentiation. Ovary in vitro culture experiments demonstrated that YAP inhibition 
blocked growth of pre-antral ovarian follicles to antral follicles by suppressing granulosa 
cell proliferation. Further, injection of Verteporfin (a selective antagonist of YAP) into 
female CD1 mice inhibited disrupted mouse ovarian follicle development in vivo. Our 
studies demonstrate that dynamic regulation of YAP activity is essential for granulosa cell 
proliferation and differentiation to support ovarian follicle development.   
3 
1.1. INTRODUCTION 
1.1.1. Ovarian granulosa cells 
The ovary is a complex organ essential for producing oocytes and secreting steroid 
hormones to achieve reproduction and maintain women’s health. The follicle is the basic 
functional unit of the ovary. Ovarian granulosa cells, which contribute to most of the 
somatic components of the ovarian follicle, can produce sex hormones and growth factors 
for follicle development (1). After a fast-growth phase in undifferentiated status, granulosa 
cells undergo differentiation under induction of the follicle stimulating hormone (FSH). 
Transgenic mouse models demonstrated that FSH-deficient females became infertile due 
to failure of antral follicle development, indicating the significance of gonadotropin-induced 
granulosa cell differentiation during follicle development (2). Under the stimulation of 
luteinizing hormone (LH), ovulation occurs, and granulosa cells exit the cell cycle and 
terminally differentiate to luteal cells for progesterone production (3). Therefore, it is 
essential that granulosa cells are coordinately regulated to proliferate and differentiate for 
follicle growth and maturation to maintain normal ovarian function. 
1.1.2. The Hippo-YAP pathway 
Recent studies suggest that the Hippo-YAP pathway controls organ development (4-
7). The Hippo-YAP pathway was first discovered in Drosophila and later found to be 
conserved in mammals. The core components of the Hippo-YAP pathway in mammals 
consist of the serine/threonine kinases Mammalian STE20-like protein kinase 1/2 
(MST1/2) and Large Tumor Suppressor kinase 1/2 (LATS1/2), the scaffold proteins 
Salvador homolog 1 (Sav1) and MOB kinase activator 1 (MOB1), and the downstream 
transcriptional coactivators Yes associated protein 1 (YAP) and WW Domain Containing 
Transcription Regulator 1 (WWTR1 or TAZ). Activation of upstream kinases by 
4 
phosphorylation leads to subsequent phosphorylation of YAP and TAZ proteins, which 
retains them in the cytoplasm and inhibits their transcriptional activity (4, 7, 8). Without 
inhibition from upstream kinases, non-phosphorylated YAP and TAZ translocate into the 
nucleus to bind with transcriptional factors such as TEA Domain Transcription Factor 
(TEAD) to activate targeting gene expression to promote cell proliferation, survival, and 
stem cell function. 
1.1.3. Yes-associated protein 1 (YAP) 
Extensive studies have recently indicated that YAP is a proto-oncogene that plays 
important roles in organ growth and tumorigenesis by regulating cell proliferation and 
apoptosis (6, 9-12). It has also been shown that YAP activity is involved in the regulation 
of cell fate in the liver, lung, intestine and skin (13-21). For example, Hippo pathway 
activation regulates maintenance of the differentiated hepatocyte state, whereas 
increased YAP activity defines hepatic progenitor identity, driving liver overgrowth and 
tumorigenesis (22). Furthermore, our previous report showed that YAP expression is 
elevated in the granulosa cell tumor (GCT) compared with normal ovaries and that YAP 
can promote GCT cell proliferation and migration (23). 
1.1.4. Previous research and present study 
Although many reports have focused on the Hippo pathway in the last decade, its role 
in the development of mammalian ovarian follicle remains unclear. Studies from 
Kawamura et.al. showed that fragmentation of ovaries stimulates follicle growth through 
disruption of the Hippo-YAP pathway (24). Cheng et.al. recently showed that 
Jasplakinolide (JASP) and sphingosine-1-phosphate (S1P) can stimulate follicle growth 
by activating YAP protein (25). However, the cell types involved in these processes and 
the underlying molecular mechanisms are not known. A recent study indicated that YAP 
5 
is dispensable for oocyte survival, growth, and maturation in mouse model (26). Thus, the 
present study focuses on the roles of YAP in regulation of granulosa cell physiology. Our 
results indicate that the dynamic regulation of YAP activity is vital for granulosa cell 
proliferation and differentiation to support ovarian follicle development for female fertility. 
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1.2. MATERIALS AND METHODS 
1.2.1.  Chemicals 
DMEM/F12 and other cell culture media were purchased from Sigma-Aldrich (St. 
Louis, MO); fetal bovine serum (FBS) was from Atlanta Biologicals, Inc. (Lawrenceville, 
GA); Alexa-conjugated secondary antibodies were from Life Technologies (Grand Island, 
NY); YAP siRNA#1 and siRNA#2 were from Dhamarcon/Thermo Scientific (Pittsburgh, 
PA); RNeasy Mini Kit was from QIAGEN Inc. (Valencia, CA); PCR reagents were from 
Invitrogen (Carlsbad, CA), QIAGEN (Carlsbad, CA) or Bio-Rad (Hercules, CA); 
Peroxidase-conjugated secondary antibodies for Western blotting were from Jackson 
Immunoresearch Laboratories Inc. (West Grove, PA); the SuperSignal West Femto 
Chemiluminescent Substrate Kit was from Pierce/Thermo Scientific (Rockford, IL); and 
the Optitran® Nitrocellular transfer membrane was from Schleicher&Schuell Bioscience 
(Dassel, Germany). 
1.2.2. Immunohistochemistry and immunocytochemistry 
Fluorescent immunohistochemistry was used to detect expression of YAP, Ki67, 3β-
HSD, and cleaved caspase-3 protein in the mouse ovary or the spheroids of 3D culture 
system. Briefly, tissues were frozen in Tissue-Tek optimal cutting temperature (O.C.T.) 
compound (Sakura Finetek Europe B.V., Flemingweg, AJ Alphen aan den Rijn, The 
Netherlands). The blocks were sectioned at 6 µm thickness using a Leica CM3050S 
instrument and attached to silane-coated slides. The frozen sections were fixed in freshly 
prepared 4% paraformaldehyde and stained using antibodies for YAP, Ki67, 3β-HSD, and 
cleaved caspase 3 protein overnight. Sections were then incubated with the appropriate 
fluorescein-labeled (red or green) secondary antibody at room temperature for 30 min in 
a humidified chamber. F-actin was stained with Rhodamine Phalloidin and nuclei were 
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labeled with DAPI. Slides were mounted with Fluoromount-G (Southern Biotech, 
Birmingham, AL) and coverslips. Images were captured using a Zeiss 710 Meta Confocal 
Laser Scanning Microscope and analyzed using Zeiss Zen 2010 software (Carl Zeiss 
Microscopy, LLC, Thornwood, NY). 
YAP, LATS1, and LATS2 expression in paraffin-embedded human ovarian tissues 
was detected using a peroxidase-based immunohistochemistry assay (VECTASTAIN 
Elite ABC HRP kit, Vector Laboratories) and immunosignals were visualized with a DAB 
kit (ImmPACT DAB Peroxidas HRP Substrate, Vector Laboratories). Stained sections 
were counterstained with hematoxylin and covered with coverslips using Sakura 
Automated Slide Stainer and Coverslipper. In negative controls, the primary antibody was 
replaced by a blocking buffer containing the same amount of IgG from non-immune rabbit 
serum. The sections were scanned with an iSCAN Coreo Slide Scaner (Ventana Medical 
Systems, Inc., Oro Valley, AZ). Paraffin-embedded normal human ovarian tissue slides 
were obtained from the Department of Pathology, Tianjin Medical University Cancer 
Hospital and University of Nebraska Medical Center (UNMC). These human tissue slides 
were used according to protocols approved by the UNMC Institutional Review Board and 
Tianjin Medical University Institutional Review Board. 
Fluorescent immunocytochemistry was used to localize YAP protein in KGN cells. 
Briefly, cells were cultured on the coverslips. After treatments, cells were fixed in freshly 
prepared 4% paraformaldehyde and stained for YAP protein as fluorescent 
immunohistochemistry. 
1.2.3. Cell collection and culture 
Primary human granulosa cells were collected from follicular aspirates of reproductive-
age patients during oocyte retrieval for in vitro fertilization (IVF) at the Heartland Center 
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for Reproductive Medicine (Omaha, NE). Patients were treated with recombinant human 
follicle stimulating hormone (FSH), followed by administration of hCG to induce follicle 
development. After hCG treatment for 35 h, oocyte and follicular fluid were retrieved under 
guidance by ultrasound. The oocyte and cumulus cells were collected for IVF. The 
remaining follicular aspirates were held on ice and sent to the laboratory for studies. The 
aspirates donated from a single patient were pooled and centrifuged at 500 g for 5 min. 
Cells were resuspended in DMEM/F12 (Fisher Scientific Inc. Pittsburgh, PA) containing 
2% penicillin-streptomycin. The cell suspension was then carefully layered onto 50% 
Percoll, and centrifuged at 800 × g for 15 min. Granulosa cells were harvested from the 
interphase of the medium and Percoll. After being washed 3 times with DMEM/F12, 
granulosa cells were seeded into 10 cm dishes with DMEM/F12 containing 1% Ultroser G 
serum substitute (Pall Corporation, Saint-Germain-en-Laye Cedex, France) and 1% 
penicillin-streptomycin. The following day, granulosa cells were trypsinized and plated into 
6-well plate for siRNA transfection or virus infection.  
The HGrC1 and KGN cell lines were purchased from the Riken Biosource Center 
(Riken Cell Bank, Tsukuba, Japan) and has been validated by short tandem repeat 
polymorphism analysis. Cells were cultured in DMEM/F12 with the addition of 1% Ultroser 
G serum substitute and 1% penicillin-streptomycin. Cells were incubated at 37 °C, 5% 
CO2, and 95% air. 
1.2.4. YAP protein knockdown and overexpression 
YAP protein knockdown was performed with YAP targeting siRNA#1 and siRNA#2 
(GE Darmacon, Lafayette, CO). Lipofactamine@ RNAiMAX Transfection Reagent (Grand 
Island, NY) was used to deliver siRNA into cells according to manufacturer instructions. 
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Using retrovirus-based YAP overexpression constructs given by Dr. Jixin Dong 
(University of Nebraska Medical Center), hGC-YAP, and hGC-YAPS127A cells were 
established with overexpression of wild-type YAP and constitutively active mutant YAP in 
primary human granulosa cells (hGC), respectively. hGC-MX cells were established as 
control with transfection of empty vector. Mutated YAP protein (S to A at residue 127) 
prevents YAP from being phosphorylated at residue 127, resulting in constitutive 
activation. Primary human granulosa cells were plated and cultured at 30 – 40% 
confluence in 6-well plates, retrovirus with MX, YAP, and YAPS127A vectors were incubated 
with cells overnight. After 72 h infection, positive cells were selected with G-418 (400 
μg/ml) for 7 days.  
1.2.5. Three-dimensional hanging drop cell culture 
A three-dimensional (3D) hanging drop culture system was employed to mimic 
granulosa cell growth in vivo. Briefly, an equal number (0.5 × 106) of hGC-MX, hGC-YAP, 
and hGC-YAPS127A cells was loaded  onto a GravityPLUS™ 3D Cell Culture plate 
(InSphero, Schlieren, Switzerland) according to manufacturer instructions. Culture 
medium was replaced everyday and and the spheroids were culured at 37 °C, 5% CO2, 
and 95% air for 7 days. Spheroids were imaged by an Olympus inverted microscopy 
(Olympus America, Inc. Center Valley, PA). The volume of spheroids ((shortest diameter)2 
× (longest diameter) × 3.14 /6) were calculated as indication of cell growth. The spheroids 
were then embeded in OCT for preparation of frozen sections. 
1.2.6. Cell proliferation analysis 
Cell numbers were monitored with an Invitrogen Countess automated cell counter after 
YAP knocked down or YAP/YAPS127A overexpressed for indicated time with proper 
controls. Trypan blue was used to identify and quantify viable cells. 
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1.2.7. Apoptosis assays 
Cell apoptosis was monitored by an Annexin V-FITC Apoptosis Detection Kit 
(BioVision Inc., San Francisco, CA) following manufacturer instructions. Briefly, after 
indicated treatments, cells were trypsinized and incubated with Annexin V-FITC and 
propidium iodide for 5 min. Flow cytometry was performed by the Flow Cytometry 
Research Facility at the University of Nebraska Medical Center to monitor apoptosis. 
1.2.8. Enzyme-linked immunosorbent assay (ELISA) 
Estradiol and progesterone levels in cell culture media and mouse serum were 
detected using ELISA assays. Medium estradiol levels were monitored using 17β-
Estradiol Enzyme Immunoassay Kit (Arbor Assays, Ann Arbor, Michigan). Progesterone 
production was detected by using Progesteron(e) ELISA kit (DRG International Inc., 
Springfield, NJ). 
1.2.9. Western blots 
Cells were harvested on ice with ice-cold cell lysis buffer (10 mM Tris pH (7.4), 100 
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 1% Triton x-100, 10% 
glycerol, 0.1% SDS, and 0.5% deoxycholate, plus protease and phosphatase inhibitor 
cocktails (Pierce/Thermo Scientific, Rockford, IL)). Each lysate was then sonicated for 3 
s. Lysates were centrifuged at 18,350 x g for 15 min at 4 °C and supernatants were 
collected for SDS-PAGE analysis. Protein concentration was determined by Bradford 
assay (Bio-Rad 500-0006). Protein samples (30 µg) were loaded with protein-loading 
buffer (50 mM Tris pH 6.8, 300 mM glycerol, 25 mM SDS, 45 mM DTT, 260 mM 2-
mercaptoethanol, and bromophenol) on 10% SDS-PAGE gel and separated by 
electrophoresis. Separated proteins were then transferred to nitrocellulose membranes, 
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which were blocked with 5% BSA in TBST (10 mM Tris-HCl, 150 mM NaCl, 0.1% Tween 
20; pH 7.5) for 1 h at room temperature. Primary antibodies diluted in TBST with 5% BSA 
were incubated with blocked membranes overnight at 4 °C or for 2 h at room temperature. 
After washing 3 times with TBST for 5 min, membranes were further probed with anti-
rabbit or anti-mouse HRP-conjugated IgG diluted in TBST with 5% BSA (1: 2,000) for 1 h 
at room temperature. After washing 3 times with TBST for 5 min, protein bands were 
detected with Thermo Scientific SuperSignal West Femto Chemiluminescent Substrate 
Kit. Images were captured and analyzed with a UVP gel documentation system (UVP, 
Upland, CA).  
1.2.10. Reverse transcriptase-polymerase chain reaction (RT-PCR) 
Total RNA was isolated from indicated cell cultures using the RNeasy mini kit (Qiagen, 
Inc.) according to manufacturer instructions. First-strand cDNA was synthesized from 1 
µg total RNA using iScript Reverse Transcription Supermix for RT-qPCR kit (Bio-Rad). 
Quantitative RT-PCR was performed with gene-specific primers and iTaq Univerisal SYBR 
green supermix by using CFX96 Real-Time System (Bio-Rad). GAPDH was used as 
normalized control. RT-PCR was performed with GoTaq Flexi DNA Polymerase (Bio-Rad). 
Products were loaded onto an agarose gel and separated by electrophoresis. Images 
were captured by UVP gel documentation system.  
1.2.11. BODIPY staining 
Fluorescent neutral lipid dye 4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-
indacene (BODIPY 493/503, green) was used to stain lipid droplets. Cells or frozen tissues 
on slides were fixed with 4% paraformaldehyde and washed with PBS for 3 x 5 min. 
BODIPY, Rhodamine Phalloidin, and DAPI diluted in normal donkey serum were 
incubated with tissues/cells for 30 min. After three 5 min washes, slides were mounted 
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with Fluoromount-G and coverslips. Pictures were captured by Zeiss 710 Meta Confocal 
laser scanning microscopy. 
1.2.12. Colony formation assays 
The role of YAP in transformation was determined using a Cytoselect 96-Well Cell 
Transformation assay kit (Cell Biolabs, Inc., San Diego, CA) according to manufacturer 
instructions. Briefly, equal numbers of cells from diverse groups were plated in 0.6% soft 
agar condition and cultured with treatments for 10 days. MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) was used to stain colonies, which were then imaged 
and counted. 
1.2.13. In vitro ovary culture 
Mouse ovaries were collected at day 12 after birth. Ovaries were excised from the 
ovarian bursa and transferred with a drop of medium onto Costar Transwell membrane 
(non-tissue culture treated, Nucleopore polycarbonate membrane, 3.0-μm pore size, 24-
well insert). About one half ml of medium (Waymouth medium MB752/1 supplement with 
0.23 mM pyruvic acid, 3 mg/ml BSA, 10% FBS, and 1% penicillin and streptomycin, 5 
ng/ml FSH (Recombinant human FSH was obtained from National Institute of Diabetes 
and Digestive and Kidney Diseases (Bethesda, MD)) was also added to support follicle 
development) had been added in the well below the membrane insert. When the drop of 
medium was add onto the membrane, the ovary was covered by only a thin film of medium. 
The medium was changed every 2 days by adding 0.5 ml of medium to the chamber below 
the membrane and then withdrawing the same volume. Cultures were incubated at 37 °C, 
5% CO2, and 95% air for 7 d. Verteporfin or vehicle was added to medium for treatments. 
At the end of experiments, ovaries were photographed and fixed. Histology and 
immunohistochemistry were performed to exam the ovarian follicle development. 
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1.2.14. In vivo YAP inhibition 
Verteporfin (VP, 50 mg/kg) or vehicle (10% DMSO in PBS, 100 μl) was injected into 
adult female CD-1 mice daily for 5 d. Ovaries and serum were collected for RNA, protein, 
IHC, and TUNEL analyses according to approved ICAUC protocols.  
1.2.15. Statistical analysis 
All experiments were performed at least three times unless otherwise noted. The data 
are presented as representative experiments or as the means ± SEM of the averages from 
multiple experiments. Statistical analysis was conducted using GraphPad Prism software 
(GraphPad Software, Inc. La Jolla, CA). Statistical comparisons between two groups were 
analyzed for significance by two-tailed Student’s t-test. Multiple group comparisons were 
assessed by one-way analysis of variance with Tukey’s post-Hoc test. P ≤ 0.05 was 




1.3.1. Expression of YAP in human and mouse ovaries 
The spatio-temporal expression of YAP during ovarian follicle development in 
mammals has not been thoroughly investigated. We monitored the expression level and 
location of YAP in both mouse and human ovaries using immunohistochemistry. 
Fluorescent immunohistochemistry analyses showed that the expression of YAP was 
mainly located in the granulosa and luteal cells of the mouse ovary (Fig. 1-1 A1, B1 , C1 & 
C0). In early granulosa cells of primary (P1) and secondary (P2) follicles, YAP was 
moderately expressed in the nuclei (Fig. 1-1 A1). In the growing follicle, granulosa cells 
are proliferative, as indicated by high expression of proliferation marker Ki67 (Fig. 1-1 A2, 
B2 & C2). In granulosa cells of growing follicles, YAP protein was highly expressed in the 
nuclei (Fig. 1-1 A1, B1, C1 & C0). However, when granulosa cells terminally differentiated 
into luteal cells, which highly expressed 3βHSD enzyme (Fig. 1-1 A3, B3 & C3), YAP was 
largely located to the cytoplasm (Fig. 1-1 A1, B1, C1 & C0), indicating inhibited YAP activity 
(9). The expression of YAP decreased dramatically in the late phase of luteal cells (lLC) 
which express less 3βHSD enzyme and undergo regression (Fig. 1-1 B1 & B3). In addition, 
LATS1 and LATS2, the upstream suppressors of YAP in the Hippo pathway, were 
detected with elevated expression in luteal cells compared with their expression in 
granulosa cells, respectively (Fig. 1-1 D1 & D2). 
A similar expression pattern was observed in human ovaries. YAP was mainly 
expressed in the nuclei of granulosa cells of early stage follicles (Fig. 1-2). In the 
differentiating granulosa cells of antral follicle, YAP expression was detected in both 
cytoplasm and nuclei (Fig. 1-2). Consistently, YAP was mainly located in the cytoplasm of 
luteal cells (Fig. 1-2). Interestingly, YAP expression was focused in the nuclei of cumulus 
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granulosa cells (cGC), though YAP tends to disperse much more in the cytoplasm of mural 
granulosa cells (mGC) (Fig. 1-2). Previous study suggested that cGC were enriched in 
transcripts for cell proliferation and mGC were enriched in transcripts associated with cell 
differentiation and steroidogenesis (27). Together, these results suggest that proliferative 
granulosa cells express active YAP protein, whereas YAP activity is gradually suppressed 
during the differentiation of granulosa cells to luteal cells. Thus, YAP may be critical in the 
regulation of proliferation and differentiation of granulosa cells. 
1.3.2. YAP promotes proliferation and survival of human granulosa cells  
The co-localization of active YAP and Ki67 staining in granulosa cells (Fig. 1-1) 
suggests that YAP may be critical for granulosa cell proliferation. Using YAP-targeting 
siRNA#1 and siRNA#2, YAP expression was efficiently knocked down in primary human 
granulosa cells (hGC) (Fig. 1-3 A), and cell proliferation was suppressed significantly after 
knockdown for 5 d (Fig. 1-3 B). YAP inhibition with siRNA#1 and siRNA#2 dramatically 
increased cell apoptosis (Fig. 1-3 C), indicating essential role of YAP to support granulosa 
cell survival. Employing a retrovirus-based system, hGC were expressed with empty 
vector (hGC-MX), wild-type YAP (hGC-YAP), or constitutively active YAP (hGC-YAPS127A, 
Serine 127 site was mutated to Alanine to avoid inhibition by LATS1/2 phosphorylation (4, 
10)) to investigate the effects of YAP overactivation in human granulosa cells. Western 
blots showed that both hGC-YAP and hGC-YAPS127A cells expressed high level of YAP 
(Fig. 1-3 D), indicating high efficiency of overexpression. Compared with high levels of 
phosphorylated YAP (S127) in hGC-YAP, hGC-YAPS127A cells had much less 
phosphorylated YAP (S127) expression, which is similar with that of control (Fig. 1-3 D). 
These results demonstrated that in hGC-YAP cells, the Hippo pathway actively 
suppressed, in some extent, overexpressed wild-type YAP, whereas hGC-YAPS127A cells 
successfully expressed constitutively active YAPS127A protein avoiding phosphorylation 
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and inhibition. Overexpression of both wild-type and constitutively active YAP significantly 
increased the proliferation of hGC, with hGC-YAPS127A cells have the most cell number 
(Fig. 1-3 E).  
To mimic the growth of granulosa cells in vivo, we established a three-dimensional 
(3D) hanging drop culture system in which cells form natural cell contacts to grow as 
spheroid structure (1, 28). YAP overexpression significantly stimulated human granulosa 
cell growth in 3D culture, indicated by the increased volume of the spheroids formed by 
hGC-YAP and hGC-YAPS127A cells compared with control (Fig. 1-3 F). Further fluorescent 
immunocytochemistry analyses showed that YAP overexpression increased Ki67 and 
decreased cleaved Caspase 3 expression (Fig. 1-3 G & H). A pharmacological inhibitor 
Verteporfin (VP), which specifically blocks YAP activity (29), reduced Ki67 and increased 
cleaved Caspase 3 expression (Fig. 1-3 G & H). Taken together, YAP stimulates 
proliferation and supports survival of human granulosa cells. 
1.3.3. YAP overexpression impairs steroidogenesis and cell differentiation 
The distinct expression pattern of YAP in granulosa cells and luteal cells suggests that 
YAP activity may negatively regulate the differentiation of granulosa cells. Gonadotropins-
induced PKA pathway activation regulates the differentiation of granulosa cells (30, 31). 
We utilized FSH and forskolin (FSK, an adenylate cyclase activator (32)) to induce 
hormone production of hGC and KGN cells with different YAP activity (hGC-MX, hGC-
YAP, hGC-YAPS127A, KGN-MX, KGN-YAP, and KGN-YAPS127A). FSK or FSH treatments 
induced hormone production in control cells as expected (Fig. 1-4 A & C). Overexpression 
of YAP or YAPS127A decreased both the basal and FSK or FSH induced production of 
estradiol and progesterone (Fig. 1-4 A & C). Interesting, YAP or YAPS127A overexpression 
almost eliminated FSH induced hormone production (Fig. 1-4 C). Quantitative PCR results 
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demonstrated that YAP overexpression reduced mRNA of steroidogenic enzymes 
aromatase (CYP19A1) and cholesterol side-chain cleavage enzyme (P450scc/CYP11A1) 
in granulosa cells with or without FSK treatment (Fig. 1-4 B). Western blot results further 
demonstrated that overexpression of YAP or YAPS127A dramatically decreased FSH- and 
FSK- induced expression of aromatase and P450scc (Fig. 1-4 D). These results indicate 
that overactivation of YAP compromised steroidogenesis of human granulosa cells by 
down-regulation of key enzymes.  
Lipid droplet formation is a marker of granulosa cell differentiation (33, 34), BODIPY 
staining showed numerous lipid droplets in the differentiated luteal cells but few in 
granulosa cells (Fig. 1-4 E). FSK treatment induced mass production of lipid droplets in 
control cells, indicating cell differentiation induced by FSK (Fig. 1-4 E). However, 
overexpression of YAP or YAPS127A reduced the formation of lipid droplets under FSK 
induction, suggesting that differentiation was impaired by YAP overactivation (Fig. 1-4 E). 
1.3.4. Overactive YAP induces dedifferentiation of granulosa cells 
To further investigate the role of YAP in cell differentiation, key molecules related to 
granulosa cell differentiation were detected by Quantitative PCR. On the one hand, YAP 
or YAPS127A overexpression significantly increased mRNA expression of Myc, and TERT 
(Fig. 1-5 A), which are important molecules for retaining stemness and are enriched in 
early granulosa cells and tumor cells (35, 36). On the other hand, overexpression of YAP 
significantly decreased mRNA expression of FSHR, CYP19A1, CYP11A1, INHA, INHBA, 
INHBB, and PLIN2, all of which are differentiation markers of granulosa cells (Fig. 1-5 A). 
Together these results suggest that YAP hyperactivity induces dedifferentiation of 
granulosa cells. 
18 
Previous studies showed that YAP can promote epithelial cells to undergo epithelial–
mesenchymal transition (EMT) (37-39). However, our results showed hyperactive YAP 
promotes mesenchymal–epithelial transition (MET) of granulosa cells by decreasing 
mesenchymal proteins including vimentin, Snail, Slug, and by elevating epithelial markers 
Claudin 1 and ZO-1 (Fig. 1-5 B). Recent studies suggested that MET is vital for cell 
reprogramming (40, 41), support our idea that YAP reprograms granulosa cells to a 
dedifferentiation status. 
1.3.5. HBEGF stimulates YAP activity and granulosa cell proliferation 
The epidermal growth factor (EGF) family plays significant role in granulosa cell 
proliferation and differentiation during follicle development (42). A previous study showed 
that HBEGF, a member of EGF family ligands, is expressed in the granulosa cells of early-
stage follicle (43). We found that YAP upregulated HBEGF expression in granulosa cells 
(Fig. 1-6 A). HBEGF stimulated granulosa cell proliferation, but suppressed production of 
both estradiol and progesterone (Fig. 1-6 B). In turn, we found that HBEGF can activate 
YAP in granulosa cells. Western blot results showed that HBEGF can dephosphorylate 
YAP at S127 site following dephosphorylation of upstream LATS1 kinase (Fig. 1-6 C). The 
phosphorylation of ERK and AKT were induced by HBEGF in 10 minutes, which occurred 
before the dephosphorylation of YAP and LATS1. These results suggest that HBEGF 
stimulates YAP activity and granulosa cell proliferation. 
1.3.6. Gonadotropin inhibits YAP activity and induces hormone production 
Then we ask how gonadotropin-induced differentiation signaling affects YAP activity. 
Both FSH and FSK were able to induce cultured granulosa cell differentiation to produce 
estradiol and progesterone (Fig. 1-6 D), whereas cell proliferation was suppressed (Fig. 
1-6 D). Interestingly, we found that FSH and FSK increased YAP phosphorylation at S127 
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site following elevated LATS1 phosphorylation (Fig. 1-6 E). The phosphorylation of CREB 
indicated that differentiation PKA signaling pathway was activated by FSH and FSK as 
expected (Fig. 1-6 E). Fluorescent immunocytochemistry results showed that the 
cytoplasmic retention of YAP was increased under FSK treatment (Fig. 1-6 F). Further, 
FSK can down regulated mRNA expression of HBEGF, which was upregulated by YAP 
(Fig. 1-6 G). These results suggest that gonadotropin-induced PKA pathway activation 
inhibits YAP activity and induces hormone production of granulosa cells. 
1.3.7. YAP overactivation promotes granulosa cell growth in soft agar 
Impairment of granulosa cell differentiation may result in uncontrolled proliferation and 
thus malignant cell transformation (44). To examine the role of YAP in the transformation 
of granulosa cells, in vitro soft agar assays were performed. Empty vector transfected 
hGC-MX cells formed few or no large colonies in the soft agar culture after seeding for 10 
d, whereas both wild-type (hGC-YAP) and constitutively active YAP (hGC-YAPS127A) 
overexpressing granulosa cells formed many large colonies (Fig. 1-7 A & B). hGC-
YAPS127A cells formed the most colonies (Fig. 1-7 A & B). Pharmacological inhibition of 
YAP by Verteporfin resulted in failure of colony formation in YAP or YAPS127A 
overexpressing cells (Fig. 1-7 A & B), indicating that YAP may promote the transformation 
of granulosa cells. To avoid potential subjective results from manual colony number 
counting, fluorescence-based cell transformation assays were used to analyze cell growth 
in the anchorage-independent culture. The results further demonstrated that YAP or 
YAPS127A overexpression stimulated human granulosa cell growth in soft agar, whereas 
inhibition of YAP activity reversed the anchorage-free growth induced by YAP 
overactivation (Fig. 1-7 A & B).  
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1.3.8. YAP inhibition results in defects of mouse follicle development  
In vitro ovary culture system was used to examine the role of YAP for ovarian follicle 
development. Mouse ovaries were collected at day 12 after birth and cultured on 
membrane with or without addition of Verteporfin (VP). After culture in vitro for 7 d, ovaries 
of control (CTL) group developed growth follicles which can be observed under 
microscopy, whereas Verteporfin treated ovaries did not show follicle growth (Fig. 1-8 A). 
Histological analyses showed antral follicles were formed in control ovaries, indicating that 
in vitro-cultured ovaries keep the same pace of follicle development with in vivo condition 
(Fig. 1-8 B). However, there is no antral follicle found in the Verteporfin treated group (Fig. 
1-8 B). Further IHC analyses demonstrated that YAP inhibition blocked granulosa cell 
proliferation and induced cell apoptosis, resulting in arrested follicle growth (Fig. 1-8 C & 
D).  
To further investigate inhibition of YAP effects on mouse follicle development in vivo, 
intraperitoneal injection of Verteporfin (50 mg/kg, daily) or vehicle was conducted for 5 d. 
Downstream YAP targeting genes Ctgf, Areg, Hbegf, Myc, and Erbb3 were downregulated 
after Verteporfin treatment (Fig. 1-8 E), suggesting YAP activity was successfully blocked 
by Verteporfin. TUNEL assay results evidenced increased apoptotic follicles in ovaries 
after Verteporfin treatment (Fig. 1-8 F). Meanwhile, 3βHSD staining showed that the 
number of corpus luteum were reduced with Verteporfin injection (Fig. 1-8 G), which was 
also supported by decreased mRNA of Hsd3b (Fig. 1-8 H), a key enzyme expressed in 
corpus luteum. Progesterone, secreted by the corpus luteum, was decreased in the blood 
of Verteporfin treated mice compared with control group (Fig. 1-8 I). These results further 






Ovarian follicle development is vital for women’s fertility and health. Ovarian granulosa 
cells are the major components of the follicle, contributing significantly to follicle growth 
and oocyte maturation (1). In this study, we demonstrate that YAP, the key downstream 
effector of the Hippo pathway, regulates granulosa cell proliferation and survival to support 
follicle growth. However, overactivation of YAP impairs differentiation of granulosa cells, 
leading to malignant transformation. Thus, our studies suggest that the orchestrated 
regulation of YAP activity is critical for granulosa cell proliferation and differentiation to 
support normal ovarian follicle development. 
1.4.2. YAP promotes granulosa cell proliferation and follicle growth 
Both fluorescent and chromogenic immunohistochemical analyses clearly showed that 
a high level of nuclear-localized YAP was expressed in the rapid-proliferating granulosa 
cells of mouse and human ovaries. These results suggest that YAP may play a key role 
in promoting granulosa cell growth, thereby stimulating overall ovarian follicle growth. 
Then we demonstrated that YAP is vital for granulosa cell proliferation and survival in vitro 
using both traditional 2D culture and a novel 3D culture system. Utilizing Verteporfin to 
block YAP activity, our in vitro ovary culture and in vivo mouse experiments further support 
the vital role of YAP in granulosa cell proliferation to support follicle growth.  
Previous studies showed that epidermal growth factor (EGF) family regulate granulosa 
cell proliferation and differentiation during follicle development (42, 45). Our previous study 
showed that TGFα promotes proliferation and migration of granulosa cell tumor cells via 
EGFR signaling (46), which has been shown to interact with YAP to regulate cell 
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proliferation (47-49). A previous study showed that HBEGF was expressed in early stage 
granulosa cells (43). Here, our results showed that nuclear YAP was highly expressed in 
proliferative granulosa cells. Overexpression of YAP upregulated HBEGF expression and 
HBEGF stimulates granulosa cell proliferation. In turn, HBEGF can activate YAP via 
inhibition of Hippo signaling component LATS1. Our previous studies suggested that YAP 
interacts with ERBB signaling and FGFR signaling to promote ovarian cancer progression 
(50, 51). ERBB signaling and FGFR signaling are also implicated in the development of 
ovarian follicles (42, 52-55). Here our data indicate that Hippo-YAP signaling may interact 
with HBEGF signaling to regulate granulosa cell proliferation and differentiation. 
1.4.3. YAP impairs GC differentiation 
In differentiated luteal cells, however, YAP was found largely in the cytoplasm, in which 
its transcriptional activity was presumably suppressed (9, 10), indicating that inactivation 
of YAP activity may be necessary for granulosa cell luteinization. In addition, LATS1 and 
LATS2 expression were elevated in luteal cells compared with granulosa cells, supporting 
that YAP activity may be suppressed by upstream Hippo signaling kinases during the 
differentiation of granulosa cells to luteal cells. Our studies demonstrated that 
overexpression of YAP impedes differentiation and induces dedifferentiation and 
anchorage-free growth of granulosa cells, suggesting malignant cell transformation. 
During ovarian follicle development, differentiation of granulosa cells was elicited by FSH, 
while terminal differentiation of granulosa cells into non-dividing luteal cells is triggered 
after ovulation by high levels of LH, where exit from the cell cycle is required to stop 
division (3, 56). Protein Kinase A (PKA) mediates gonadotropin signals to induce 
granulosa cell differentiation (57). Our results demonstrate that gonadotropin-induced 
differentiation signals inactivate YAP by phosphorylation, resulting in proliferation arrest 
and increase of hormone production. On the other hand, HBEGF, which activates YAP, 
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stimulates proliferation and decreased hormone production of granulosa cells. The 
presence of lower levels or lack of LH receptor in GCTs suggests that loss of LH 
stimulation may lead to failure of granulosa cell luteinization, contributing to GCT formation 
(44, 58). Our results showed that overactive YAP can suppress expression of 
differentiation genes, resulting in failure of granulosa cell differentiation and uncontrolled 
proliferation. However, the mechanism of suppressive effects of YAP on the expression 
of differentiation genes need further studies. 
1.4.4. Hippo-YAP signaling in follicle development 
It is becoming clear that the Hippo signaling pathway constrains ovarian follicle growth 
(1, 24). Previous studies showed that LATS1-null female mice presented a primary ovarian 
insufficiency (POI) phenotype and developed ovarian tumors (59, 60), and LATS1 
regulates the transcriptional activity of FOXL2, which is mutated in most of granulosa cell 
tumor patients and some POI patients (61). In addition, Genome-wide association study 
(GWAS) of polycystic ovary syndrome (PCOS) implicated YAP as a susceptibility gene for 
PCOS (62). More importantly, recent studies in Dr. Hsueh’s lab shed lights on novel 
therapy for PCOS by showing that temporary activation of YAP with physical 
fragmentation or chemical treatments using JASP or S1P can promote ovarian follicle 
growth (24, 25). The authors proposed that YAP activation in the whole ovary can 
stimulate follicle development, however, the exact cell types involved in these process is 
unclear. Our results demonstrate that YAP is vital for promoting growth and survival of 
granulosa cells to support follicle growth, which provides the underlying mechanism of 
why activation of YAP can stimulate follicle growth. Importantly, our study indicates that 
granulosa cells may be the target cells for treating patients with defects of ovarian follicle 
development. Recently, Yu et al demonstrated that YAP is dispensable for the survival, 
growth and maturation of mouse oocytes (26), which further support our idea that 
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granulosa cells are the targets of Hippo-YAP signaling regulation for follicle development. 
However, hyperactivation of YAP impairs steroidogenesis and differentiation of granulosa 
cells, leading to malignant transformation of granulosa cells. Taken together, our study 
suggests that YAP activity should be dynamically regulated for granulosa cell proliferation 
and differentiation to support follicle development and reminds us to be cautious and 
meticulous when treating patients with ovarian failure by activation of YAP. 
1.4.5. Conclusion 
In conclusion, our data show that YAP is mainly expressed in the proliferative 
granulosa cell nuclei and the cytoplasm of luteal cells. The YAP activity promotes 
granulosa cell proliferation but prevents cell differentiation. HBEGF signaling activates 
YAP and stimulate proliferation. On the other hand, gonadotropin-induced PKA activation 
inhibits YAP activity and stimulate granulosa cell differentiation. YAP inhibition blocks 
granulosa cell proliferation, resulting in arrested follicle growth and increased apoptotic 
follicles. However, overactive YAP compromises cell differentiation and promotes 
malignant transformation of granulosa cells. Therefore, the orchestrated regulation of YAP 
activities is vital for granulosa cell physiology to support follicle development and ovarian 
function.  
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Figure 1-1. Expression of YAP and LATS1/2 in various stages of mouse ovarian 
follicles.  
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Figure 1-2. The expression of YAP with the development of ovarian follicles in 
human.  
The chromogenic immunohistochemistry shows YAP expression in human ovaries. P0: 
primordial follicle; P1: primary follicle; P2: secondary follicle; GC: granulosa cells; cGC: 
cumulus granulosa cells; mGC; mural granulosa cells; LC: luteal cells; SC: stromal cells; 







Figure 1-3. YAP promotes proliferation and supports survival of human granulosa 
cells.  
A) Western blots showing YAP protein knockdown with YAP-targeting siRNA#1 and 
siRNA#2 for 5 d. β-Actin was used as loading control. 
B) Representative pictures show growth suppression of hGC under YAP targeting siRNA 
incubation for 5 d; the bar graph showing cell number counted 5 d after hGC cells were 
transfected with control or YAP-targeting siRNA; scale bar: 200 μm.   
C) YAP knockdown induces apoptosis of human granulosa cells: representative images 
show Annexin V-FITC/propidium iodide double staining of hGC 5 d after transfection with 
control or YAP siRNA; the bar graph showing quantitative data for the ratio of Annexin V 
positive cells.  
D) Western blots show YAP and phosphor-YAP (S127) expression in hGC-MX, hGC-YAP, 
and hGC-YAP
S127A
 cells, using β-Actin as loading control. 
E) Representative images showing multilayer-growth of hGC after YAP overexpression; 
bar graph showing cell number counting after plating for 5 d; scale bar: 200 μm.   
F) Overexpression of YAP promotes human granulosa cell growth in a 3D culture system: 
representative images showing the spheroids from hGC-MX, hGC-YAP, and hGC-
YAP
S127A
 cells for 5 d; the bar graph showing quantitative data for the volume of spheroids; 
scale bar: 500 μm.  
G) Representative images showing Ki67 staining in spheroids formed by hGC-MX, and 
hGC-YAP
S127A
 cells with vehicle (DMSO, 0.1%) or Verteporfin (VP, 5 μM) treatment for 5 
d; the bar graph showing quantitative data for the KI67 ratio; scale bar: 20 μm.  
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H) Representative images showing cleaved caspase 3 (C-Cas 3) staining in spheroids 
formed by hGC-MX, and hGC-YAP
S127A
 cells with vehicle (DMSO, 0.1%) or Verteporfin 
(VP, 5 μM) treatment for 5 d; the bar graph showing quantitative data for the cleaved 
caspase 3 ratio; scale bar: 20 μm.  
Each bar represents the mean ± SEM (n ≥ 4). Bars with different letters are significantly 






Figure 1-4. YAP overactivation compromises cell steroidogenesis and impedes cell 
differentiation  
A) Overexpression of YAP or YAPS127A decreased base (CTL) and forskolin (FSK) induced 
production of estrogen and progesterone in primary human granulosa cells.  
B) Quantitative RT-PCR results show mRNA expression of CYP19A1 and CYP11A1 in 
primary human granulosa cells with different YAP activity.  
C) Overexpression of YAP or YAPS127A reduced base and FSH or FSK induced production 
of estradiol and progesterone in KGN cells.  
D) Western blot results show expression of key enzymes for steroidogenesis of KGN cells 
with different YAP activity. 
E) BODIPY staining showing lipid droplets distribution; upper panel: BODIPY staining 
(green) showing the distribution of lipid droplets in mouse ovaries; lower panel: BODIPY 
staining shows that YAP overexpression retarded FSK-induced lipid droplet formation; 
scale bar = 50 um.  
Each bar represents the mean ± SEM (n ≥ 4). When compared with control, *: P < 0.05, 





Figure 1-5. YAP hyperactivation induces dedifferentiation of granulosa cells.  
A) mRNA expression of key molecules of differentiation in KGN cells with YAP or YAP
S127A
 
overexpression; each bar represents the mean ± SEM (n ≥ 3); when compared with control, 
*: P < 0.05, **: P < 0.01, ***: P < 0.001.  
B) Western blots showing the expression of proteins related to mesenchymal–epithelial 
transition (MET) after YAP or YAP
S127A






Figure 1-6. HBEGF and Gonadotropins regulate YAP activity and granulosa cell 
proliferation and steroidogenesis.  
A) Overexpression of YAP upregulated HBEGF mRNA expression in hGC, HGrC1, and 
KGN cells.  
B) HBEGF treatment (50 ng/ml, 3 d) stimulated cell proliferation and suppressed 
production of estradiol and progesterone.  
C) Western blots showed that HBEGF (50 ng/ml) dephosphorylated YAP at S127 site 
following LATS1 (S909) dephosphorylation; ρ-ERK and ρ-AKT were increased before 
dephosphorylation of LATS1; β-Actin was used as loading control.   
D) Bar graphs show the effects of FSH (50 ng/ml, 3 d) and forskolin (FSK, 10 μM, 3 d) on 
the estrogen and progesterone production and cell proliferation.  
E) Western blots showed that FSH (50 ng/ml) and FSK (10 μM) stimulate YAP 
phosphorylation of S127 site following LATS1 (S909) phosphorylation; ρ-CREB was used 
to show activation of PKA and β-Actin was used as loading control.  
F) Forskolin (FSK) treatment (10 μM, 60’) increased YAP retention in the cytoplasm. Scale 
bar = 20 μm.  
G) Forskolin (FSK) treatment (10 μM, 3 d) decreased HBEGF mRNA expression. 
Each bar represents the mean ± SEM (n ≥ 3). When compared with control (CTL), * means 






Figure 1-7. YAP promotes granulosa cell growth in soft agar.  
A) Representative pictures showing colony formation in soft agar of hGC-MX, hGC-YAP, 
and hGC-YAP
S127A
 cells with or without Verteporfin (VP) incubation; scale bar: 500 um.  
B) Bar graphs showing colony number counting and relative fluorescent unit (RFU) to 
reflect viable cells in soft agar culture; each bar represents the mean ± SEM (n ≥ 4); when 







Figure 1-8. Inhibition of YAP disrupts ovarian follicle development in vitro and in 
vivo.  
A) Representative images showing morphology of d 12 mouse ovaries cultured for 7 d in 
vitro with Verteporfin (VP) or not (CTL); scale bar: 500 μm.  
B, C, D) Representative images showing H & E, Ki67, and cleaved Caspase 3 staining of 
cultured mouse ovaries respectively; yellow arrows and cycles indicating antral follicles in 
control group; scale bar: 50 μm.  
E) Yap and targeting gene expression in the control and Verteporfin injected mouse 
ovaries were detected with RT-PCR and western blots.  
F) TUNEL assays show YAP inhibition increases the number of apoptotic follicles; scale 
bar: 500 μm.  
G) YAP inhibition decreases corpus luteum number; 3βHSD staining represent corpus 
luteum location.  
H) Bar graph showing the RNA expression of 3βHSD in control (CTL) and Verteporfin (VP) 
injected mouse ovaries; scale bar: 500 μm. 
I) YAP inhibition by Verteporfin (VP) decreases progesterone level of mouse serum. 
Each bar represents the mean ± SEM (n ≥ 3). When compared with control (CTL), * means 
P < 0.05; ** means P < 0.01; *** means P < 0.001. 




CHAPTER 2: YAP PROMOTES GRANULOSA CELL TUMOR 
PROGRESSION† 
  
                                               
† The material presented in this chapter was previously published: Fu & Lv et al. Endocrine-
Related Cancer 2014; 21(2):297-310. 
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ABSTRACT 
The Hippo signaling pathway has been implicated as a conserved regulator of organ 
size in both drosophila and mammals. Yes-associated protein (YAP), the central 
component of the Hippo signaling cascade, functions as an oncogene in several 
malignancies. Ovarian granulosa cell tumors (GCT) are characterized by enlargement of 
the ovary, excess production of estrogen, a high frequency of recurrence, and the potential 
for malignancy and metastasis. Whether the Hippo pathway plays a role in the 
pathogenesis of GCT is unknown. This study was conducted to examine the expression 
of YAP in human adult GCT and to determine the role of YAP in the progression of GCT 
cells. Compared with age-matched normal human ovaries, GCT tissues exhibited higher 
levels of YAP expression. YAP protein was predominantly expressed in the nucleus of 
tumor cells, whereas the non-tumor ovarian stromal cells expressed very low levels of 
YAP. YAP was also expressed in cultured primary human granulosa cells and in KGN and 
COV434 GCT cell lines. siRNA-mediated knockdown of YAP in KGN cells resulted in a 
significant reduction in cell proliferation (P < 0.001). Conversely, overexpression of wild 
type YAP or a constitutively active YAP (YAPS127A) mutant resulted in a significant increase 
in KGN cell proliferation and migration. These results demonstrate that YAP plays an 
important role in the regulation of GCT cell proliferation and migration. Targeting the 
Hippo/YAP pathway may provide a novel therapeutic approach for GCT.  
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2.1. INTRODUCTION 
2.1.1. The Hippo-YAP pathway in organ size control and tumorigenesis 
The balance between cell growth and death plays a vital role in the maintenance of 
tissue homeostasis, organ size, and normal biological functions of the human body. Under 
physiological conditions, cell growth and apoptosis are tightly controlled. Aged or 
damaged cells commit to programed cell death, whereas adult stem cells may divide and 
differentiate to replace those dysfunctional cells to maintain tissue homeostasis and organ 
size. Under pathological conditions, however, uncontrolled cell proliferation and 
decreased cell death and/or differentiation can lead to hyperplasia or even tumorigenesis. 
The mechanisms underlying the control of organ size are still largely unknown. Studies 
have shown that the Hippo signaling pathway (Salvador/Warts/ Hippo pathway) plays a 
critical role in controlling organ size by regulating both cell proliferation and apoptosis in 
both Drosophila and mammals (8, 9, 63) 
Yes-associated protein 1 (YAP1, also known as YAP) is the major downstream effector 
of the Hippo pathway (64). The expression and role of YAP in cancer are cell-type- and/or 
cellular-context-dependent (64, 65). Amplification of the YAP gene locus at 11q22 is found 
in hepatocellular carcinoma, breast cancer, oral squamous cell carcinomas, 
medulloblastomas, and esophageal squamous cell carcinomas (37, 66-69). In addition, 
overexpression and nuclear localization of YAP protein are found in colon, liver, lung, 
ovarian, and prostate cancers (8, 10, 67, 70). Moreover, overexpression of YAP leads to 
oncogenic transformation of an immortalized epithelial cell line MCF10A (37). However, 
YAP enhances p73-dependent cell death during cisplatin-induced DNA damage (65, 71), 
indicating that YAP may interact with other pathways to optimize a tumor suppressor 
response. In a subset of breast cancers, the expression of YAP protein was significantly 
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decreased due to loss of heterozygosity, and short hairpin RNA (shRNA) knockdown of 
YAP increased migration and invasiveness, and enhanced tumor growth (72). Therefore, 
the expression and function of YAP in specific cancers requires further investigation. 
2.1.2. Etiology of granulosa cell tumor 
Granulosa cell tumors of ovary (GCT), accounting for 70% of malignant sex-cord 
stromal tumors and 5–8% of all ovarian malignancies, are poorly understood ovarian 
neoplasms (73). Patients with GCT have a high overall survival rate, which is mainly 
attributed to diagnosis of GCT at an early stage. The prognosis is significantly poorer for 
patients with advanced tumors. The 10-year survival rates in stage III and IV are lower 
than 20% (74). Clinically, GCT have a propensity for late recurrence (75, 76). 
Approximately, 80% of patients with advanced stage or recurrent tumors succumb to their 
disease due to the limited treatment options for advanced and recurrent disease (73, 77). 
These tumors also have malignant potential and metastatic ability. Indeed, metastases 
from GCT have been reported in the lung, liver, brain, bone, diaphragm, abdominal wall, 
pancreas, and adrenal gland (78).  
Some factors and pathways have been shown to affect the development of GCT (73). 
Importantly, recent studies have shown that a somatic mutation in FOXL2 (C402G) is a 
potential driver in the pathogenesis of adult-type GCT (79-84). However, the exact 
mechanisms underlying GCT progression, recurrence, and metastasis are largely 
unknown. Oftentimes, GCT are hemorrhagic and manifest as painful abdominal masses, 
with an average diameter more than 10 cm (74, 85-87). Occasionally, the diameter of the 
GCT tumor can be over 30 cm (86, 88-90). This volume is several hundred-fold larger than 
the regular human ovary, which is around 5 cm3. The significant increase in the volume of 
the ovary indicates that the system controlling organ size in the patients with GCT is 
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disrupted. As GCT are derived from ovarian granulosa cells, the proliferation of granulosa 
cells in the patient’s ovary may be deregulated. However, the molecular pathology 
underlying this remarkable increase in tissue size is unknown.  
2.1.3. The present study 
In this study, we compared YAP expression in normal human ovarian tissues and GCT 
tissues using immunohistochemistry. YAP was also consistently detected in ovarian GCT 
cell lines. We also examined the role of YAP in the regulation of GCT cell proliferation and 
migration using the KGN human GCT cell line as a cellular model. Our results indicate 




2.2. MATERIALS AND METHODS 
2.2.1. Chemicals 
Human FSH was from NHPP/NIDDK (Torrance, CA, USA). DMEM/F12 and other cell 
culture medium were from Invitrogen. FBS was from Atlanta Biologicals, Inc. 
(Lawrenceville, GA, USA). The Ribogreen RNA quantification kit and Alexa-conjugated 
secondary antibodies were from Life Technologies Corp.; YAP small interfering RNA 
(siRNA) was from Dhamarcon/Thermo Scientific (Pittsburgh, PA, USA). Secondary 
antibodies for western blotting chemiluminescence were from Jackson Immunoresearch 
Laboratories, Inc. (West Grove, PA, USA); PCR reagents were from Invitrogen, Qiagen or 
Bio-Rad. All other molecular-grade chemicals were purchased from Sigma, Fisher 
(Pittsburgh, PA, USA), or United States Biochemical (Cleveland, OH, USA). 
2.2.2. Cell lines and human GCT tissue slides 
The KGN cell line, an adult GCT cell line expressing a mutated FOXL2 (C402G) gene, 
was obtained from the Riken BioSource Center (Riken Cell Bank, Ibaraki, Japan). The 
COV434 cell line, a juvenile GCT cell line expressing wildtype FOXL2 gene, was received 
from Dr. C E van der Minne (University Hospital, Leiden, The Netherlands). The SKOV-3 
ovarian cancer cell line was purchased from the American Type Culture Collection (ATCC, 
Manassas, VA, USA). The IGROV-1 ovarian cancer cell was received from Dr. Bo Reuda 
(Massachusetts General Hospital, MA, USA). Human ovarian granulosa cells isolated 
from two medium-sized follicles (5–10 mm in diameter) were obtained from a 33-year-old 
patient who received oophorectomy for causes other than an ovarian disorder. The 
collection of this tissue was permitted by a protocol approved by the University of 
Nebraska Medical Center Institutional Review Board. The cells were isolated manually 
with a needle and cultured in DMEM/F12 supplemented with 5% FBS. All cell lines used 
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in this study were passaged fewer than ten times in our laboratories and were validated 
for their authenticity by short tandem repeat (STR) analysis. Formalin-fixed, paraffin-
embedded normal human ovarian tissues (n = 10) and human GCT (n = 12) slides were 
obtained from the Department of Pathology, Tianjin Medical University Cancer Hospital 
and UNMC. The retrospective use of these human tissue slides was permitted by 
protocols approved by the UNMC Institutional Review Board and Tianjin Medical 
University Institutional Review Board.  
The KGN GCT cells were derived from a patient with recurrent, metastasized GCT in 
the pelvic region (91). These cells maintain many features of ovarian granulosa cells such 
as expression of the FSH receptor and induction of aromatase (CYP19A1) and production 
of estrogen in response to FSH. To date, to our knowledge, the KGN cell line is the only 
appropriate cellular model for studying the growth and metastasis of the adult GCT (80, 
92). In this study, we examined the role of YAP in the proliferation and migration of KGN 
cells. The KGN cells used in these experiments were from passages 6 to 10. The cell line 
was validated by STR polymorphism analysis performed by both the Riken BioSource 
Center (Riken Cell Bank) and the Genetica DNA Laboratories (Burlington, NC, USA). 
2.2.3. Immunohistochemistry analysis of YAP expression in ovarian tissues 
The expression of YAP protein in paraffin-embedded human ovarian tissues was 
detected using a previously described peroxidase-based immunohistochemistry protocol 
(46). Immunosignals were visualized with a 3,3’-diaminobenzidine (DAB) kit (Invitrogen). 
The sections were counterstained with Mayer’s hematoxylin. In case of negative controls, 
the primary antibody was replaced by blocking buffer containing the same amount of IgG 
from non-immune rabbit serum. The sections were scanned with an iSCAN Coreo Slide 
Scaner (Ventana Medical Systems, Inc., Oro Valley, AZ, USA). The positivity (i.e., the 
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number of positively stained cells relative to the total number of cells in the tissue section) 
and the intensity of the positive immunosignals were quantified with Aperio ImageScope 
software (Vista, CA, USA). 
2.2.4. Localization of YAP protein in KGN cells  
KGN cells were seeded onto glass coverslips and incubated in a growth medium 
(DMEM/F12 supplemented with 5% FBS) for 36 h before fixation in ice-cold 4% 
paraformaldehyde for 10 min. Staining was performed using methods described 
previously (46). The fixed cells were incubated with YAP antibody (1:100) overnight at 4 
°C in a humidified chamber. Antigens were visualized by applying Alexa-488-conjugated 
donkey anti-rabbit secondary antibodies. Actin filaments were stained with rhodamine-
conjugated phalloidin and the nuclei were stained with 4’,6-diamidino-2-phenylindole 
(DAPI). The images were captured and analyzed with an LSM 710 confocal microscope 
(Thornwood, NY, USA). The exposure time of the camera was set for subtracting 
background fluorescence that was present in the sections incubated with the nonimmune 
IgG of the host species. YAP-specific fluorescence signals (immunosignal) were merged 
with the nuclear and actin signals to determine the sub-cellular site of protein expression. 
2.2.5. YAP mRNA expression 
YAP mRNA expression in GCT cell lines was detected with RT-PCR as described 
previously (46). Total RNA was isolated from primary cultures of normal human granulosa 
cells, cultured GCT cell lines (KGN cells and COV434 cells), and epithelial ovarian cancer 
(EOC) cells (SKOV-3, CAOV-3, and IGROV-1 cells) using the RNeasy mini kit (Qiagen, 
Inc.) according to the manufacturer’s instructions. The first-strand cDNA was synthesized 
from 1 μg total RNA using iScript cDNA synthesis kit (Bio-Rad). PCR products were loaded 
onto an agarose gel and separated by electrophoresis. The images were captured by a 
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UVP gel documentation system (UVP, Upland, CA, USA). The PCR products were 
validated by sequence analysis. 
2.2.6. Western blot analysis 
Western blot was performed as described previously. Briefly, normal cell lines or 
treated KGN cells were harvested on ice with ice-cold cell lysis buffer containing 10 mM 
Tris (pH 7.4), 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 1% 
Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate and protease and phosphatase 
inhibitor cocktails. Proteins (30 μg) were loaded onto a 10% SDS–PAGE gel, separated 
by electrophoresis, and transferred onto nitrocellulose membranes. The membranes were 
blocked with 5% BSA and probed with appropriate primary and HRP-conjugated 
secondary antibodies. The immunosignal was detected with a Thermo Scientific 
SuperSignal West Femto Chemiluminescent Substrate Kit. The images were captured and 
analyzed with a UVP gel documentation system. 
2.2.7. Establishment of wild-type and mutant YAP overexpressed cell lines 
KGN cells were cultured to 40% confluence and then transfected with retrovirus-based 
human YAP expression constructs. The characteristics and use of these vectors have 
been reported previously (9). Two days following transfection, cells were selected with G-
418 (400 μg/ml) for 7 days. Three stable cell lines were established: i) the KGN–MXIV 
control cell line was transfected with the control vector MXIV and expresses endogenous 
YAP; ii) the KGN–YAP cell line overexpresses wild-type YAP protein; and iii) the KGN–
YAPS127A cell line expresses a constitutively activated YAP mutant. Mutation of YAP 
protein (serine to alanine at residue 127) prevents YAP phosphorylation, leading to its 
nuclear localization and constitutive activation. 
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2.2.8. Cell proliferation assay 
To determine the effect of YAP on GCT cell proliferation, KGN cells were plated in 60 
mm cell culture dishes and incubated in a growth medium supplemented with 5% FBS 
until 60% confluent. The cells were then transfected with siGLO (a cy5-labeled non-
targeting siRNA as control) or YAP siRNA for 6 h using METAFECTENE (Biontex-USA, 
San Diego, CA, USA) according to the manufacturer’s instructions. The cells were 
harvested 72 h after siRNA transfection for determination of protein levels or cell numbers. 
YAP protein expression was determined by western blot analysis and the cell numbers 
were quantified with an Invitrogen Countess automated cell counter. The effect of YAP on 
GCT cell proliferation was also determined in KGN cell lines that overexpressed the WT 
or mutant YAP proteins. Each cell line was cultured in the growth medium containing 10% 
FBS for up to 3 days. Cell number and cell size for each cell line were determined daily 
with an Invitrogen Countess Automated cell counter. 
2.2.9. Cell migration assay 
A chemotaxis assay was used to determine the effect of YAP on KGN cell migration. 
KGN cells (4 × 105) in 250 μl of serum-free DMEM were placed in a Transwell insert (8 
μm pore size, Corning-Costar, Lowell, MA, USA). The inserts were then placed in the wells 
of a 24-well-plate containing 750 μl of DMEM-FBS (5%) and incubated at 37 °C for 6 h. 
After incubation, the cells on the top of the membrane were removed with a cotton swab. 
The cells which had migrated to the underside of the membrane were fixed and stained 
with 0.04% crystal violet in methanol for 30 min. The cells were then photographed (100 
× magnification) and ten pictures per group were quantified under a microscope. 
The wound-healing assay was also used to determine whether YAP regulates KGN 
cell motility. KGN cells were cultured in six-well cell plates until confluent. Wounds were 
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made by scratching the cell layer with a 100 μl pipette tip. After washing away the cell 
debris, pictures were taken for each ‘wound’ with an Olympus inverted microscope 
equipped with a DP71 digital camera (Olympus America, Inc., Center Valley, PA, USA). 
The cells were incubated in serum-free medium for 20 h and then another picture was 
taken for each ‘wound’. 
2.2.10. Statistical analysis 
All experiments were repeated at least three times unless otherwise noted. Data were 
analyzed for significance by student T-test or one-way ANOVA with Tukey’s post-test. A 
value of P < 0.05 was considered to be significant. Statistical analysis was conducted 




2.3.1. Expression of YAP protein in GCT 
Adult GCT are commonly identified in women during the perimenopausal period (73). 
The expression of YAP in the normal human ovary and GCT was detected by 
immunohistochemistry. In control perimenopausal ovarian sections, the main cellular 
component and the stroma, exhibited very little or no staining for YAP (Fig. 2-1 A, C, and 
E). In control ovarian sections, few small follicles or luteinized structures were observed. 
When follicles were present, YAP immunosignals were detected in granulosa cells and 
were distributed in both nucleus and cytoplasm (too few follicles, data not shown). When 
luteinized cells were present, YAP was predominantly localized to the cytoplasm (Fig. 2-
1 C and E). Compared with the control ovarian tissues, YAP immunosignals were 
significantly increased (P < 0.001) in the GCT tumor tissues and the protein was 
predominantly located in the nucleus of tumor cells (Fig. 2-1 B, D, and F). Nontumor 
stromal cells had low levels of YAP expression. Immunostaining controls revealed no non-
specific staining in GCT tissues (Fig. 2-1 G). The intensities of YAP immunostaining 
signals were quantified with Aperio imagescope software (Aperio). The data showed that 
both YAP signal intensity and YAP positivity (percentage of the YAP positive cells relative 
to the total number of cells per section) in the ovarian GCT tissues were significantly higher 
than the signals in the normal ovarian tissues (Fig. 2-1 H, P < 0.001).  
2.3.2. Expression of YAP in ovarian GCT tumor cell lines 
As mentioned earlier, the KGN cell is a suitable cellular model for the GCT research. 
Fluorescent immunocytochemistry showed that YAP is expressed in KGN cells (Fig. 2-2 
A). Most of the immunosignal was localized to the nucleus. Interestingly, the YAP 
immunosignal was also localized to punctate regions in the periphery of the cells that co-
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localized with β-actin (Fig. 2-2 A). It is very possible that YAP may interact with the focal 
adhesion proteins. Antibody controls using the same amount of IgG to replace the primary 
YAP antibody were not stained (Fig. 2-2 A, lower panel). 
RT-PCR and western blot analysis showed that YAP mRNA and YAP protein were 
expressed in primary cultures of human granulosa cells, KGN and COV434 GCT cell lines 
(Fig. 2-2 B and C). YAP RNA and YAP protein were also expressed in three ovarian 
epithelial cancer cell lines (Fig. 2-2 B and C). IGROV-1 cells had lower expression of YAP 
compared with SKOV-3 and CAOV-3 cells. It is well known that YAP protein activity is 
highly regulated by phosphorylation. Western blot analysis revealed that phospho-
YAP(S127) was present in each of the cell lines. Our results also showed that compared 
with the KGN cells YAP was less phosphorylated in COV434 cells (Fig. 2-2 B and C), a 
juvenile GCT cell line (73, 80). 
2.3.3. Knockdown of YAP expression in KGN cells inhibits cell proliferation 
To explore the role of YAP in GCT cell proliferation, we transiently transfected KGN 
cells with two YAP siRNAs to knock down YAP expression. Cy5-labeled scrambled siRNA 
(siGLO) was used as a control. Results showed that the transfection efficiency was very 
high in the KGN cells, with more than 95% of cells being siGLO positive (Fig. 2-3 A). 
Western blot analysis revealed that both YAP siRNA1 and siRNA 2 significantly (P < 
0.001) reduced YAP protein in KGN cells (Fig. 2-3 B). The YAP knockdown KGN cells 
were only 50–60% confluent compared with siGLO-treated cells, which were nearly 100% 
confluent (Fig. 2-3 C). Quantification of cell numbers showed that compared with the 
normal KGN cells or the KGN cells treated with siGLO, the cell numbers in the YAP 
knockdown KGN cells was significantly reduced (~55%; P < 0.001; Fig. 2-3 D). 
Knockdown of YAP not only suppressed cell proliferation but also affected cell 
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morphology. As shown in Fig. 2-3 C, YAP-knockdown KGN cells were more spindle-
shaped compared with control KGN cells, indicating that YAP may regulate the actin 
cytoskeleton of the KGN cells.  
2.3.4. Overexpression of YAP promotes KGN cell proliferation and migration  
To further explore the role of YAP in GCT cell proliferation, we established cell lines 
which express the wildtype YAP protein (KGN-YAP) or the constitutively active YAP 
protein (KGN-YAPS127A). The empty vector (MX) was also transfected into KGN cells and 
served as a control cell line (KGN-MX). Results showed that compared with the control 
cell line (KGN-MX), both KGN-YAP and the KGN-YAPS127A cells expressed more YAP 
protein (Fig. 2-4 A). Morphologically, KGN-YAPS127A cells were smaller and much more 
elongated compared with control cells (Fig. 2-4 B). Compared with the control group, cell 
numbers almost tripled in KGN-YAPS127A cells and almost doubled in KGN-YAP cells within 
24 h of plating (Fig. 2-4 C). After 3 days of culture, the number of KGN-YAPS127A cells 
increased more than ten-fold, the number of KGN-YAP cells increased more than six-fold, 
while the number of control cells (KGN-MX) increased only 2.5-fold (Fig. 2-4 C). We also 
found that in comparison to the KGN-MX control cells, the diameter of KGN-YAP and 
KGN-YAPS127A cells was reduced.  
Transwell migration assays showed that cells in KGN-YAP group migrated faster than 
cells in KGN-MX group, while cells in the KGN-YAPS127A group migrated faster than cells 
in the KGN-YAP group (Fig. 2-5 A and B). This result was further confirmed by the wound-
healing assay (Fig. 2-5 C). The morphology of the migrated cells further demonstrated 
that the KGN-YAPS127A cells were smaller than the corresponding control KGN-MX cells 




2.4.1. Overview of previous studies and the present study on GCT 
More than one and half centuries have passed since the first report of GCT in women 
(93). The etiology and mechanisms underlying the progression and metastasis of GCT 
are largely unknown. GCT are derived from granulosa cells, which are highly regulated by 
reproductive hormones and growth factors in an endocrine, paracrine, and autocrine 
manner (94, 95). Therefore, hormones, growth factors, and signaling pathways involved 
in the regulation of normal ovarian granulosa cell functions may also affect the initiation 
and/or progression of GCT. Indeed, several hormones and growth factors have been 
implicated in the development of GCT. Inhibin-α has been suggested to be a critical GCT 
tumor suppressor in rodents because the targeted deletion of the inhibin-α subunit in mice 
resulted in ovarian granulosa-stromal tumors with very high penetrance (96). However, 
human GCT are generally associated with high levels of circulating inhibins (97). 
Therefore, the function of inhibin in the development of GCT in humans requires further 
evaluation. Transgenic mice with constitutively activated WNT/b-catenin signaling in their 
granulosa cells developed GCT (98), indicating that the WNT/b-catenin signaling pathway 
maybe involved in the rodent GCT initiation and progression. However, it remains unclear 
if the molecular mechanisms of tumorigenesis in this mouse model are related to those 
involved in GCT development in women. A more recent whole transcriptome sequencing 
study with human samples has demonstrated that a somatic mutation in FOXL2 (C402G; 
Cys134TrP) was present in almost all morphologically identified adult-type GCT and 
indicated that mutant FOXL2 is a potential driver in the pathogenesis of adult-type GCT 
(79, 80). More recently, Rosario et al. found that patients with homozygous FOXL2 
mutations had a significantly higher relapse rate (P < 0.04). However, they did not find a 
significant correlation between FOXL2 mutation status or FOXL2 expression and any 
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other clinical variables. The author’s indicated that due to the limitation of the sample size, 
the prognostic significance of this gene mutation still needs to be confirmed (99). 
Therefore, although nearly all adult GCT express the mutant FOXL2 gene, the 
mechanisms underlying the progression, recurrence, and metastasis of ovarian GCT 
remain unknown. In this study, our data clearly show that YAP, a central component of the 
Hippo pathway, is highly expressed in human GCT tissues and that overexpression of 
YAP protein significantly stimulates the proliferation and migration of the KGN GCT cell 
line, demonstrating that the Hippo pathway may be involved in the progression of GCT. 
2.4.2. YAP expression in GCT and ovarian epithelial cancer 
YAP is the major downstream effector of the Hippo pathway. Activation of the Hippo 
pathway suppresses YAP activity by phosphorylating YAP and subsequently retaining it 
in the cytoplasm. In this study, we found that YAP immunostaining was significantly higher 
in human GCT tumor tissues compared with normal ovarian tissues. Moreover, YAP was 
mainly localized in the nucleus of tumor cells. In comparison, little YAP protein was found 
in age-matched normal ovarian tissues. When luteinized cells were present in age-
matched normal ovarian tissues, YAP was mainly localized to the cytoplasm. Consistent 
with our results, elevated YAP expression and nuclear localization have been observed in 
multiple types of human cancers, including liver cancers, colon cancers, EOC, lung 
cancers, and prostate cancers (9, 10, 67, 70). In hepatocellular carcinoma, YAP was 
determined to be an independent prognostic marker for overall survival and disease-free 
survival (100). In EOC, very recent data indicated that subcellular levels of YAP showed 
an exceptionally strong association with poor patient survival (101). The authors 
suggested that high levels of nuclear YAP, or low levels of cytoplasmic phosphorylated 
YAP, were associated with poor survival in patients with EOC. Patients with both high-
nuclear YAP and low-phosphorylated YAP had about 50% lower 5-year survival, and this 
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combination serves as an independent prognostic marker for survival (101). In another 
study, levels of active nuclear YAP were reported to be expressed at high levels in around 
14% of a cohort of 284 human ovarian cancer samples. Segregation by histotype showed 
that the correlation between nuclear YAP and poor survival is predominantly associated 
with clear cell tumors, independent of stage (102). As patient survival data are not 
available for the samples used in this study, we cannot correlate YAP expression data 
with survival of GCT patients. However, the high level of expression and nuclear location 
of YAP protein in samples from GCT patients indicate that YAP may play important role in 
regulation of GCT progression. 
2.4.3. YAP promotes GCT progression 
Control of ovarian cell proliferation is critical for the normal function of the ovary. 
Uncontrolled granulosa cell proliferation and decreased cell death and/or differentiation 
can lead to hyperplasia of the granulosa layer and the formation of GCT. Our results 
indicate that dysregulation of the Hippo/YAP signaling pathway may contribute to 
uncontrolled granulosa cell proliferation and development of GCT which expands the size 
of the ovary. We used the KGN cell line as a model to determine the role of YAP in GCT 
cell proliferation. Consistent with the results from the patient samples, 
immunohistochemical and molecular studies showed that KGN cells express YAP. 
Knockdown of YAP protein in KGN cells with YAP-targeting siRNA significantly 
suppressed cell proliferation without reducing cell viability, indicating that YAP is critical 
for the proliferation of KGN cells. Furthermore, overexpression of YAP or its constitutively 
active mutant (YAPS127A) in KGN cells stimulated KGN cell proliferation and migration, 
indicating that the Hippo/YAP pathway may play a very important role in the regulation of 
GCT cell growth and potentially GCT cell metastasis. Taken together, our results indicate 
that YAP protein is required for the proliferation of KGN cells and the Hippo/YAP pathway 
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might be one of the major pathways that are involved in the regulation of GCT progression. 
To our knowledge, this is the first direct evidence showing the function of the Hippo/YAP 
pathway in the progression of GCT. 
The mechanism by which YAP regulates GCT cell proliferation is unclear. Granulosa 
cells are highly regulated by gonadotropins, steroid hormones, and growth factors. 
Abnormal activities in the pathways activated by any of these factors may induce 
transformation of follicular granulosa cells and may promote GCT tumor growth, 
recurrence, or metastasis. As a major effector of the Hippo pathway, YAP was reported to 
interact with many important factors associated with GCT development. For example, YAP 
has been reported to regulate the Wnt/b-catenin pathway in colorectal cancer. β-catenin 
has been reported to be a potential initiator of GCT (98, 103). YAP was also reported to 
interact with the TGFβ signaling pathway (104), which is a critical regulator of granulosa 
cell proliferation (105). We have recently found that TGFα, via EGFR signaling pathways, 
plays an important role in the proliferation of GCT cells (46). Interestingly, YAP was 
reported to interact with EGFR to regulate cell proliferation (48, 106, 107). Future studies 
on the interaction between the Hippo pathway and these critical regulators of ovarian 
function may reveal novel mechanisms by which YAP promotes the initiation and/or 
progression of GCT. 
2.4.4. Conclusion 
In conclusion, our data show that YAP is highly expressed in human GCT tissues and 
is a critical regulator of proliferation and migration in the KGN human GCT cell line. We 
propose that the Hippo-YAP signaling pathway may be involved in the regulation of GCT 
growth and progression. YAP may be a potential novel biomarker for GCT diagnosis and 
a promising target for the development of drugs for GCT therapy. 
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Figure 2-1. YAP is expressed in human granulosa cell tumors (GCT). 
Immunohistochemistry was used to examine the expression of YAP in normal ovarian 
tissues (A, C, and E) and human GCT tissues (B, D, and F). YAP staining is indicated in 
brown. The counter stain is hematoxylin, shown in blue. A) Whole-tissue section scan of 
a representative normal ovary stained with YAP antibody; B) Scanned image of partial 
ovarian GCT tissue stained with YAP. Amplified representative images of normal ovarian 
tissues (C) and GCT tissues (D) stained with YAP antibody to show cell-type-specific YAP 
expression. Representative high-resolution images were also presented to show the 
subcellular localization of YAP in the normal ovarian tissues (E) and GCT tissues (F). 
Tissue sections probed with the same amount of non-immunized rabbit IgG were used as 
antibody control (G). (H) Quantitative results of DAB intensity were also presented to show 
the difference of positivity (percentage of the number of DAB positive cells relative to 
number of total cells in each tissue section) and relative intensity of YAP immunosignal 
between normal human ovarian tissues (CTRL) and tumor tissues (GCT). Each bar 
represents the mean ± S.E.M. *: P < 0.001 when compared with the control (CTRL) 
groups. Scale bars = 2 mm in A and B; scale bars = 100 µm in C and D; scale bars = 50 





Figure 2-2. YAP is expressed in human ovarian GCT cell lines and epithelial ovarian 
cancer cell lines.  
A) Localization of YAP protein in KGN cells using fluorescent immunocytochemistry. (A1) 
Total YAP (green); (A2) YAP protein (green) merged with actin filaments (red, stained with 
Rhodamine-phalloidin). The nucleus was stained with DAPI (blue). (A3) KGN cells stained 
with same amount of rabbit IgG (antibody control) and Rhodamine-phalloidin. Scale bars 
= 25 um.  
B) RT-PCR detection of YAP mRNA expression in cultured human granulosa cells 
(human-GC), GCT cell lines (KGN and COV434) and ovarian cancer cell lines (IGROV-1, 
SKOV-3, and CAOV-3). GAPDH was used as mRNA loading control. 
C) Western blot detection of YAP protein expression in the same cell lines. β-tubulin was 







Figure 2-3. YAP is required for KGN cell proliferation.  
A) Fluorescence-labeled scramble siRNA (siGLO) indicates siRNA transfection efficiency 
in KGN cells.  
B) Western blot shows the downregulation of YAP protein after YAP siRNA treatments. β-
tubulin was used as a protein loading control. The lower panel shows the quantitative 
results for the western blot. Bars represent means ± S.E.M. (n = 3).  
C) Morphology of siGLO-transfected and YAP siRNA-transfected KGN cells. Scale bars = 
100 µm.  
D) KGN cells were transfected with YAP siRNAs for 6 h and then cultured for another 72 
h. Cell numbers in each group were determined with an INVITROGEN Countess 
automatic cell counter. Each bar represents the mean ± S.E.M. (n = 5). Bars with the 







Figure 2-4. Overexpression of YAP stimulates KGN cell proliferation.  
A) Empty plasmid-transfected KGN cells (KGN-MX), wildtype YAP overexpression cells 
(KGN-YAP), and mutant YAP-transfected KGN cells (KGN-YAPS127A) were plated in six-
well plates and the levels of YAP and phosphorylated YAP in these established stable cell 
lines were examined by western blot. β-tubulin was used as a protein loading control.  
B) Upper panel: morphological difference between mutant YAP-transfected KGN cells 
(KGN-YAPS127A) and Empty plasmid-transfected KGN cells (KGN-MX). Scale bars = 100 
µm. Lower panel: actin filaments stained with Rhodamine-phalloidin to demonstrate the 
morphological change between the two established cell lines. Nuclei were stained with 
DAPI. Scale bars = 25 µm.  
C) Effect of YAP overexpression on KGN cell proliferation. Control KGN cells (KGN-MX), 
KGN-YAP cells, and KGN-YAPS127A cells were incubated for 24, 48, and 72 h, respectively, 
and the cell number was counted with an INVITROGEN Countess automatic cell counter. 
Each bar represents the mean ± S.E.M., n = 5. Bars with the same letter are not 





Figure 2-5. YAP regulation of KGN cell migration.  
A) KGN-MX cells, KGN-YAP cells, and KGN-YAPS127A cells were loaded to a Transwell 
migration assay chamber and the migration assay was performed as described in the 
materials and methods section. Top panel, representative image of the migrated KGN-MX 
cells. Lower panel, representative image of the migrated KGN-YAPS127A cells. Scale bars 
= 100 µm.  
B) Migrated cells in each group were counted and the fold change (relative to the KGN-
MX control group) of the migrated cells was determined. Each bar represents the mean ± 
S.E.M. (n = 12). Bars with the same letter are not significantly (P < 0.05) different from 
each other.  
C) Evaluation of the cell migration ability with the wound-healing assay. Representative 





CHAPTER 3: YAP INDUCES HIGH-GRADE OVARIAN CANCER WITH 
MESENCHYMAL FEATURE FROM POORLY DIFFERENTIATED 
GRANULOSA CELLS‡ 
  
                                               
‡ The material presented in this chapter was submitted as a manuscript: Lv et al. 2017. 
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ABSTRACT 
Understanding the cell-of-origin of high-grade serous ovarian cancer (HGSOC) is the 
prerequisite for efficient prevention and early diagnosis of this most lethal gynecological 
cancer. However, the cell-of-origin of HGSOC is under debate. Recently, a novel 
mesenchymal subtype of HGSOC with poor prognosis was identified by both The Cancer 
Genome Atlas (TCGA) and Australian Ovarian Cancer Study (AOCS) studies. But the cell-
of-origin of this subtype of HGSOC has not been defined. Our previous studies 
demonstrated the critical role of Yes-associated protein 1 (YAP) in the development of 
ovarian cancer. In the present study, we show that YAP can induce high-grade ovarian 
cancer from poorly differentiated granulosa cells. Employing xenograft mouse models, 
overactive YAP elicited malignant ovarian cancer development in the peritoneal cavity of 
host mice from granulosa cells. Histologically and genetically, tumors developed in our 
mouse models resembled women’s HGSOC. Intriguingly, these tumors overexpressed N-
cadherin and vimentin but had low expression of CA125 and E-cadherin, reminiscent of 
the recently identified mesenchymal subtype of HGSOC. Our studies suggest the 





3.1.1. High-grade serous ovarian cancer 
Ovarian cancer is the most lethal gynecological cancer, ranking the fifth leading 
cancer-related death in women. In worldwide, 238,700 women are estimated to be 
diagnosed with ovarian cancer annually, with 151,900 ovarian cancer associated deaths 
(108). Ovarian cancers are collective tumors with distinguished features and origins. High-
grade serous ovarian cancer (HGSOC), which accounts for 70-80% ovarian cancer death, 
is the most common and lethal ovarian cancer (109, 110). HGSOC patients almost always 
are diagnosed at advanced clinical stages. The aggressive nature of this disease makes 
the patients have a very poor overall survival. The obstacles for the early diagnosis and 
better treatments for HGSOC are the controversial cell of origin and the unclear molecular 
etiology of this disease.   
3.1.2. Origin of HGSOC 
More often than not by the time the disease has been detected the cancer cells are 
already widespread to other tissues or organs, making it challenging to assess origin of 
HGSOC (111). Supported by studies from epidemiology, pathology, genetics, and animal 
model, fallopian tube secretory epithelial cells (FTSECs) are recognized as the cell origin 
of a substantial proportion of HGSOC, although it is called ovarian cancer (110). 
Increasing evidence indicated that HGSOCs originate as serous tubal intraepithelial 
carcinomas (STICs) located on distal oviductal fimbriae, however, the development of 
some HGSOCs seem to come from somewhere other than the fallopian tube since only 
about 60% of HGSOCs have been found accompanied by STICs (112, 113). An 
alternative origin is the lining epithelial of cortical inclusion cysts in the ovary, which are 
considered to be derived from the invaginations of ovarian surface epithelium (OSE) (114, 
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115). Mesothelial OSE cells are believe to retain stem-cell characteristics including 
pluripotency and thus can undergo serous metaplasia to further develop HGSOC (116). 
3.1.3. Novel mesenchymal subtype of HGSOC  
Next generation sequencing technology made it possible to classify HGSOC based on 
their genomic signature. By mining The Cancer Genome Atlas (TCGA) database and 
analyzing the gene expression profile of ovarian high-grade serous cancer patients, the 
TCGA group described 4 subtypes of ovarian HGSOC, termed “differentiated”, 
“immunoreactive”, “proliferative”, and “mesenchymal” subtypes (117). Consistently, an 
earlier study by the Australian Ovarian Cancer Study (AOCS) Group identified subtypes 
of HGSOC consistent with this classification (118). Importantly, both studies identified the 
mesenchymal type of HGSOC with poor prognosis (117, 118). This subtype of HGSOC 
has a mesenchymal or dedifferentiated phenotype, with overexpression of N-cadherin and 
vimentin but low expression of conventional ovarian cancer marker CA125 and E-
cadherin. The cell-of-origin of the newly identified mesenchymal type of HGSOC is yet to 
be identified.   
3.1.4. Ovarian granulosa cells 
Ovarian granulosa cells contribute to most of the somatic component of ovarian follicle. 
The proliferation and differentiation of granulosa cells are critical regulated to support 
follicle growth and oocyte maturation. The granulosa cell tumor (GCT) is thought to 
originate from differentiated granulosa cells of the late preovulatory follicle, maintaining 
many features of these cells including hormone production and response to gonadotropins 
(73). Expressing stem/tumor cell markers like MYC, KLF4, and TERT, poorly differentiated 
granulosa cells at early-stage follicles possess properties of stem/ tumor cells, including 
multipotential, indefinite self-renewal, loss of cellular contact inhibition, and anchorage-
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free growth (35, 119-121). With mesenchymal features, granulosa cells have been 
demonstrated to transdifferentiate to neuron-like cells, osteoblasts, and chondrogenic 
lineages (120, 122).  
3.1.5. Hippo-YAP signaling 
First discovered in Drosophila, the Hippo-YAP pathway is highly conserved among 
species. The Hippo-YAP pathway has attracted growing interest in the research field due 
to its fundamental role in organ size control, stem cell function, and tumorigenesis (4, 7, 
123). The transcriptional co-activator Yes-associated protein 1 (YAP) is the pivotal effector 
of the Hippo-YAP pathway. The Hippo pathway can phosphorylate YAP and subsequently 
exclude it from the nucleus to inhibit transcriptional activity of this oncoprotein (4, 5). 
Extensive studies have shown that YAP is overexpressed in a broad range of human 
cancer and promotes tumorigenesis (4, 64). YAP is also highly expressed in 
stem/progenitor cells in intestine, skin, liver, nerve, lung, heart, and muscle tissues, which 
is critical for stem/progenitor cell function (124, 125). Our previous reports demonstrated 
that YAP is overexpressed in ovarian cancers including HGSOC and YAP plays a 
significant role in the initiation and progression of ovarian cancers by interaction with 
ERBB and FGFR signaling pathways (23, 50, 51). 
3.1.6. Present study 
In the present study, unexpectedly, we found that overactive YAP elicited development 
of high-grade ovarian cancer with characteristics of mesenchymal type from poorly 
differentiated ovarian granulosa cells in xenograft mouse models, reminiscent of the 
mesenchymal subtype of HGSOC identified recently in women patients (117, 118). Our 
research unveiled a novel potential cell-of-origin of the mesenchymal type of HGSOC. 
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3.2. MATERIALS AND METHODS 
3.2.1. Cell culture 
HGrC1 cell lines was obtained from the Riken Biosource Center (Riken Cell Bank, 
Ibaraki, Japan). Cell lines were validated using short tandem repeat (STR) polymorphism 
analysis performed by Genetica DNA Laboratories (Burlinton, NC, USA). Cells were 
cultured in DMEM/F12 with supplement of Ultroser G serum substitute and antibiotics at 
37 ◦C, 5% CO2, and 95% air condition. 
3.2.2. Retrovirus system for overexpression 
HGrC1 cells were overexpressed with YAP or YAPS127A vectors (given by Dr. Jixin 
Dong at University of Nebraska Medical Center) and p53R175H vector (a gift from Dr. Jeffrey 
N Myers at MD Anderson Cancer Center). Empty vector transfected HGrC1 cells were 
used as control. Recombinant retrovirus was generated as following: after co-transfecting 
HEK293GP cells with equal amounts of VSVG packaging vector and one of the following 
retroviral expression vectors: pMX-neo-YAP, pMX-neo-YAPS127A, pBABE-puro-p53R175H 
using Lipofactamine@ 3000 Transfection Reagent (Grand Island, NY), medium was 
replaced overnight. Viral supernatants were harvested at 48 h and 72 h post transfection 
by passing through a 0.45-μm filter. Then these viruses can be stored at -80 ◦C or directly 
used to infect target cells with 8 μg/mL polybrene overnight, followed by fresh medium 
change. After 72 h post infection, appropriate selective antibiotics were added to the 
culture medium to select positive cells (HGrC1-YAP, HGrC1-YAPS127A, HGrC1-p53R175H, 
HGrC1-YAPS127Ap53R175H). The selection period lasted more than 1 week until no cells 
survival in the uninfected wells. 
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3.2.3. CRISPR Cas9 system to knockout BRCA1 
The lentivirus containing CRISPR Cas9 system vectors to knockout BRCA1 gene were 
purchased from Applied Biological Materials Inc. (Richmond, BC, CANADA). Target cells 
were infected with lentivirus overnight and selected with puromycin after 72 h infection 
similarly as retrovirus infection procedure. 
3.2.4. Cell proliferation analyses 
Cell numbers were monitored with an Invitrogen Countess automated cell counter as 
described in chapter 1. 
3.2.5. Western blot 
Cell lysis was harvested and protein was analyzed by western blot as above 
description in chapter 1. 
3.2.6. Three-dimensional hanging drop cell culture 
A three-dimensional (3D) culture system, GravityPLUS™ 3D Cell Culture plate 
(InSphero, Schlieren, Switzerland), was employed to mimic cell growth in vivo as 
described in chapter 1.  
3.2.7. Colony formation assays 
Cell transformation in vitro was determined using a Cytoselect 96-Well Cell 
Transformation assay kit (Cell Biolabs, Inc., San Diego, CA) according to the 
manufacturer’s instructions. Briefly, equal numbers of cells in different group as indication 
were plated in 0.6% soft agar condition and cultured with treatments or not for 10 days. 
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MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was used to stain 
colonies, which were then imaged and counted.  
3.2.8. Immunohistochemistry and immunocytochemistry 
Immunohistochemistry and immunocytochemistry analyses were performed using 
indicated antibodies as description in chapter 1.  
3.2.9. Hematoxylin and eosin stain for histology analyses 
Mouse xenografts were harvested and fixed with formalin. After paraffin-embedding 
and section, Hematoxylin and eosin (H & E) stain was performed for xenograft tissue 
slides. Histology analyses was conducted by the pathologist Dr. Yun-An Tseng at 
University of Nebraska Medical Center. 
3.2.10. Alcian blue pH 2.5-periodic acid–Schiff stain  
To determine the production of sulfated and carboxylated acid mucopolysaccharides 
and sialomucins in the tumor tissues, Alcian blue pH 2.5-periodic acid–Schiff (PAS) stain 
was performed. The colorectal epithelium tissues were used as a positive control for PAS 
stain. The sections were counter-stained with hematoxylin. 
3.2.11. Xenograft mouse model  
Cells (2 × 107) were trypsinized and collected by centrifugation. Cells in the pellet were 
suspended in 250 μl of DMEM/F12 with 250 μl of Matrigel (BD Biosciences Inc.) on ice. 
This mixture was injected subcutaneously or intraperitoneally into 5-week-old female Nude 
(Nu/J, Envigo) or NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, The Jackson Laboratory # 
005557) mice. Mice were closely monitored after cell implantation. For intraperitoneal 
injection, after mice became very sick with distention in abdomen and weight loss, mice 
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were euthanized and solid tumors were collected for preparation of protein, RNA and 
paraffin tissue sections. The ascites was harvested and ascites cells were separated by 
centrifuge for culture. All animal experiments were approved by the Institutional Animal 
Care and Use Committee (IACUC) at University of Nebraska Medical Center.  
3.2.12. Array Comparative Genomic Hybridization (aCGH).   
Genomic DNA extracted from xenografts, cultured ascites cells, and control HGrC1 
cells was hybridized with normal reference DNA to the Cancer Microarray (Agilent 180K 
CGH+SNP Array, CCMC design, GRCh37) to perform aCGH profiling. This array targets 
genes associated with cancer at 5-10 kb copy number resolution and provides 25 kb whole 
genome copy number coverage for precise breakpoint delineation. Copy number changes 
> 500 kb in size will be reported as well as copy-neutral loss of heterozygosity (LOH). 
3.2.13. Statistical analysis 
All experiments were performed at least three times unless otherwise noted. The data 
are presented as representative experiments or as the means ± SEM of the averages from 
multiple experiments. Statistical analysis was conducted using GraphPad Prism software 
(GraphPad Software, Inc. La Jolla, CA). Statistical comparisons between two groups were 
analyzed for significance by two-tailed Student’s t-test. Multiple group comparisons were 
assessed by one-way analysis of variance with Tukey’s post-Hoc test. P ≤ 0.05 was 




3.3.1. Overactive YAP induces malignant tumors from poorly differentiated human 
granulosa cells 
To explore the role of YAP in the malignant transformation of early-stage granulosa 
cells, we used HGrC1 as cellular model, which is an immortalized human granulosa cell 
line derived from poorly differentiated granulosa cells in the early stage of ovarian follicle 
development (126). As described above, we established HGrC1-MX (control), HGrC1-
YAP (expressing wild-type of YAP), and HGrC1-YAPS127A (expressing constitutively active 
YAP) three cell lines (Fig. 3-1 A). Overexpression of both wild-type and constitutively 
active YAP dramatically accelerated granulosa cell growth compared with control, while 
HGrC1-YAPS127A grew most rapidly (Fig. 3-1 B). In the 3D culture system, overexpression 
of wild type or constitutively active YAP significantly increased the volume of spheroids, 
with HGrC1-YAPS127A group forming the largest spheroids (Fig. 3-1 C). These results 
demonstrate that YAP overactivation promotes granulosa cell overgrowth.  
To examine the role of YAP in the malignant transformation of undifferentiated 
granulosa cells in vitro, we performed soft agar assays. As immortalized non-transformed 
HGrC1 cells, control HGrC1-MX cells formed few or no colonies in the soft agar culture 
(Fig. 3-1 D). In contrast, HGrC1-YAP and HGrC1-YAPS127A cells formed many colonies, 
and HGrC1-YAPS127A cells formed more colonies than HGrC1-YAP (Fig. 3-1 D). These 
results suggested that YAP induces malignant transformation of poorly differentiated 
HGrC1 granulosa cells.  
Consistent with in vitro experiments, HGrC1-YAP and HGrC1-YAPS127A cells, but not 
HGrC1-MX cells, formed tumors after subcutaneous injection of these cells into the nude 
mice (Fig. 3-1 E). Tumors derived from HGrC1-YAPS127A cells grew significantly faster than 
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those derived from HGrC1-YAP cells (Fig. 3-1 F & G). Surprisingly, histological analysis 
showed that tumors derived from HGrC1-YAP and HGrC1-YAPS127A cells were not like 
typical granulosa cell tumors. H & E staining showed that tumor cells in xenograft tissues 
have pleomorphic nuclei, but not typical coffee bean-like nuclei (Fig. 3-1 H). These tumor 
tissues have no typical histological structures of GCT such as Call-Exner bodies, 
trabecular pattern, or macrofollicular structures (Fig. 3-1 H). These tumor cells were very 
proliferative, indicated by high mitotic index in the H & E staining, and the high expression 
of Ki-67 (Fig. 3-1 H & I).  Moreover, IHC studies showed that these tumor cells have 
undetectable expression of aromatase which is the biomarker of GCT (Fig. 3-1 I). YAP 
staining confirmed the overexpression of YAP in tumor cells (Fig. 3-1 I). In addition, tumor 
cells were malignant, with invasion into adjacent adipose and muscle tissues. Together, 
these tumors are more likely poorly differentiated ovarian cancers, rather than granulosa 
cells tumors. 
3.3.2. YAP overactivation induces malignant ovarian cancers like high-grade 
serous ovarian cancer from granulosa cells 
Because TP53 mutations are identified in most of ovarian cancer patients, mutant 
TP53 is considered as a driver mutation in the pathogenesis of ovarian cancer (127, 128). 
To mimic the genetic alternations of ovarian cancer, we introduced the mutant p53R175H 
into HGrC1 cells. In vitro studies showed that mutant p53 (HGrC1-p53R175H) alone cannot 
transform HGrC1 cells, as indicated by the colony formation assays (Fig. 3-2 A). 
Introduction of p53R175H into HGrC1-YAPS127A cells (HGrC1-YAPS127Ap53R175H) slightly 
increased colony formation (Fig. 3-2 A). As an ovarian cancer susceptibility gene, BRCA1 
gene mutations predispose women to ovarian cancer and more than 20% of ovarian 
cancer patients have been found to have loss-of-function BRCA1, including inherited 
mutations, somatic mutations, and promoter methylation (128). With the introduction of 
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BRCA1 gene deletion by the CRISPR Cas9 system, HGrC1-YAPS127Ap53R175HBRCA1-/- 
cells formed more colonies compared with HGrC1-YAPS127Ap53R175H group, suggesting the 
significant role of BRCA1 in ovarian cancer development. 
Most patients diagnosed with ovarian cancer present at later stages, at which ovarian 
cancer cells have spread in the peritoneal cavity. To mimic the environment of ovarian 
cancer development, we intraperitoneally injected HGrC1-CTL, HGrC1-p53R175H, HGrC1-
YAPS127A, HGrC1-YAPS127Ap53R175H, and HGrC1-YAPS127Ap53R175HBRCA1-/- cells into NSG 
mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, The Jackson Laboratory # 005557) to monitor 
cancer development. Consistent with in vitro studies, all mice implanted with HGrC1 cells 
with overactive YAP (HGrC1-YAPS127A, HGrC1-YAPS127Ap53R175H, and HGrC1-
YAPS127Ap53R175HBRCA1-/- 3 groups) developed malignant cancers, accompanied by 
abdomen distension and weight loss (Fig. 3-2 B). Late stage cancers were associated with 
large amount of ascitic fluid in the peritoneal cavity (Fig. 3-2 B). After open the abdomen, 
we found that tumors were widespread in the peritoneal cavity and metastasized to 
multiple organs/tissues including diaphragm, mesentery, peritoneum, pancreas, and liver 
(Fig. 3-2 B), which is reminiscent of the typical presentation of malignant human ovarian 
cancer. Histological analyses further support the metastasis of tumors to multiple 
organs/tissues in the peritoneal cavity and also metastasis to outside muscle tissues, 
indicating the malignance of these tumors (Fig. 3-2 C). Moreover, the Kaplan-Meier 
survival analysis of these host mice showed that all tumor-burden mice died in 6 months 
(Fig. 3-2 D). HGrC1-YAPS127Ap53R175HBRCA1-/- hosted mice start to die at 2 months after 
injection, while HGrC1-YAPS127A and HGrC1-YAPS127Ap53R175H injected mice had similar 
survival time and started to die after injection for 3 months (Fig. 3-2 D). The median 
survival times are 99 days for HGrC1-YAPS127Ap53R175HBRCA1-/- mice, 130 days for 
HGrC1-YAPS127Ap53R175H mice, and 127.5 days for HGrC1-YAPS127A mice, respectively 
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(Fig. 3-2 D). Log-rank test suggested that mutation of TP53 (p53R175H) had no significant 
effect on the mouse survival rate. However, deficiency of BRCA1 gene in the 
YAPS127Ap53R175H mice significantly hastened the onset of death and reduced survival time 
(P < 0.001) (Fig. 3-2 C), indicating BRCA1 loss promotes ovarian cancer development.  
Hematoxylin and eosin staining showed the histology of tumors resembled HGSOC 
(129, 130). Tumor cells are distinct pleomorphism and marked nuclear atypia, with 
prominent nucleoli (Fig. 3-2 C). These tumor tissues have a very high mitotic index, 
including many abnormal mitotic figures (Fig. 3-2 C). Tumor cells isolated from the ascitic 
fluid were very proliferative in culture and nuclear atypia is a common feature of these 
cells. Consistently, immunohistochemistry analysis showed that proliferation marker Ki67 
is highly expressed in tumor tissues (Fig. 3-3 A). Moreover, WT1, PAX8, MYC, and keratin 
7 proteins were detected in the tumor cells with immunohistochemistry (Fig. 3-3 A), which 
are characteristics of ovarian HGSOC (129, 131). YAP and p53 expression in the tumor 
cells were confirmed (Fig. 3-3 A & D). In addition, tumor tissues were stained negative for 
aromatase and inhibin, which are two markers for granulosa cell tumors (Fig. 3-3 B). 
PAX2, a marker for low grade serous carcinoma, and mucinous ovarian cancer marker 
cytokeratin 20 were also negative in the immunohistochemistry examination (Fig. 3-3 B) 
(132, 133). We further determined that tumor tissues were negative for Alcian blue (pH 
2.5)-periodic acid–Schiff (PAS) staining, confirming that these tumors are not mucinous 
ovarian cancers (Fig. 3-3 C) (134). These findings support pathological diagnoses that 
these tumors are like HGSOC, but not other ovarian tumors.  
Western blot results further confirmed the expression of WT1, PAX8, MYC and keratin 
7 in tumor cells (Fig. 3-4). Interestingly, we found overactive YAP induced increasing 
protein expression of WT1, PAX8, and MYC in poorly differentiated granulosa cell HGrC1 
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(Fig. 3-4). The expression of YAP, p53, and BRCA1 were also confirmed by Western blots 
(Fig. 3-4). 
One of the most important features of HGSOC is genome instability (128, 135), we 
performed array comparative genomic hybridization (aCGH) to examine whether tumors 
developed in our mouse models resemble human HGSOC at the genomic level. YAP 
overactivation induced considerable genome instability in tumor cells (Fig. 3-5). Combined 
with YAP overactivation, p53 mutation, and BRCA1 deletion, tumors cells presented 
multiple regions of DNA gain and loss, indicating severe genome instability, which is the 
genomic feature of human HGSOC (Fig. 3-5).  
3.3.3. YAP induces high-grade ovarian cancers with mesenchymal features from 
granulosa cells 
Interestingly, these tumor cells retain some mesenchymal features of ovarian 
granulosa cells. We detected an elevated level of mesenchymal markers like N-Cadherin 
and vimentin but a low level of CA125 and E-Cadherin expression in these tumors with 
immunohistochemistry and western blot analyses (Fig. 3-3 A & B and Fig. 3-4). Recently, 
TCGA and AOCS studies identified a novel molecular subtype of high-grade serous 
carcinoma in patients which reflect a mesenchymal cell type, with overexpression of 
mesenchymal markers including N-cadherin and vimentin but with low CA125 and E-
cadherin expression (117, 118). This mesenchymal type HGSOC predicts a reduced 
overall survival (117, 118). With similar aggressive mesenchymal features, the tumors 





3.4.1. YAP induces high-grade ovarian cancers from poorly differentiated 
granulosa cells 
In the present study, we show that overactive YAP induced HGSOC with 
mesenchymal features from poorly differentiated granulosa cells. Tumor cells in 
subcutaneous xenograft tissues have pleomorphic nuclei in high-grade ovarian cancer 
(129, 136), but not coffee bean-like nuclei in GCT (137). These tumors also do not have 
typical histological characteristics of GCT like Call-Exner bodies, trabecular pattern, or 
macrofollicular structures (137). Moreover, these tumor tissues have very high mitotic 
index, which is indicated by the presence of many cells with mitotic figures and the high 
expression of Ki-67. Furthermore, IHC studies showed that these tumor cells have 
undetectable aromatase and inhibin, which are biomarkers of GCT. Based on the histology 
and molecular features, these tumors are more like poorly differentiated ovarian 
carcinoma but not like GCT.  
After intraperitoneal implantation of YAPS127A overexpressing granulosa cells (HGrC1-
YAPS127A, HGrC1-YAPS127Ap53R175H, and HGrC1-YAPS127Ap53R175HBRCA1-/- cells), large 
amounts of ascites in the peritoneal cavity were induced in the later stage of tumor 
progression. These tumor cells were very invasive and metastasized to the omentum, 
mesentery, visceral fat tissue, diaphragm membrane, liver, pancreas, and muscle tissues. 
Histological studies showed that the nuclei of these tumor cells are highly pleomorphic 
and larger with coarsely clumped chromatin. Moreover, these tumor tissues have very 
high mitotic index, including many abnormal mitotic figures. Furthermore, cultured tumor 
cells derived from the ascitic fluid were very proliferative and the nuclear atypia was very 
common. In addition, the known biomarkers for HGSOC, such as high Ki-67, PAX8, WT1, 
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Keratin 7 are expressed in the cancer cells derived from all three YAPS127A expressing 
cells (129, 132, 138). The morphological features and negative expression of PAX-2 in 
these tumor cells suggest that these tumors are not low-grade serous carcinomas (129). 
The negative keratin 20 and PAS staining suggests that these tumors are not mucinous 
ovarian cancers (132). The molecular features of these tumors indicated that these tumors 
are high-grade ovarian carcinoma with serous features. 
3.4.2. YAP elicits mesenchymal subtype of HGSOC from poorly differentiated 
granulosa cells 
Both the TCGA and AOCS studies revealed multiple subtypes of human HGSOC, 
including “differentiated”, “immunoreactive”, “proliferative”, and “mesenchymal” 4 
subtypes (117, 118). Of importance herein, both groups identified a mesenchymal type of 
HGSOC with poor prognosis (117, 118). Due to its mesenchymal molecular features, the 
cell-of-origin for the newly identified mesenchymal type of HGSOC remains unknown. 
However, it is known that this type of HGSOC has very high level of mesenchymal markers 
including N-cadherin and vimentin, but it has very low expression of epithelial proteins like 
E-cadherin and CA125 (MUC16) (117, 118). In the present study, we found that 
overactivation of YAP in the poorly differentiated ovarian granulosa cells induced HGSOC-
like tumors. Importantly, these tumors express high levels of N-cadherin and vimentin but 
have low expression of E-cadherin and CA125. Granulosa cells are mesenchymal type of 
ovarian cells, which can be induced to differentiate into osteoblast, muscle cells and 
neurons (120, 122). The tumor cells derived from poorly differentiated granulosa cells in 
our mouse models kept their mesenchymal cell markers such as N-cadherin and vimentin. 
Based on these novels findings, we speculate that poorly differentiated granulosa cell 
could be a potential cell-of-origin of the lethal mesenchymal type of HGSOC. 
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The mechanism by which YAP induces the mesenchymal type of HGSOC from 
granulosa cells is unclear. Granulosa cells are very special cells in human body. Previous 
studies have shown that a subpopulation of granulosa cells in early-stage follicles (poorly 
differentiated granulosa cells) possess properties of stem or tumor cells, including loss of 
cellular contact inhibition and anchorage-free growth (119, 121, 139, 140).  Isolated 
granulosa cells express stem cell markers with high telomerase activity, and can 
differentiate into other cell types (120, 141, 142). This evidence suggests that poorly 
differentiated granulosa cells are mesenchymal cells with high plasticity. As an 
oncoprotein, YAP has also been implicated in stem cell function of embryonic stem cells, 
adult stem cells, and cancer stem cells (125). Importantly, YAP has been shown to be 
overexpressed in cancer stem cells and high-grade carcinomas (68, 143, 144). Very 
recent studies show that YAP was able to induce terminally differentiated luminal breast 
epithelial cells, neurons, and the pancreatic acinar cells into tissue specific pluripotent cells 
(145). Therefore, it is possible that disruption of the Hippo pathway in granulosa cells leads 
to overactivation of YAP, which may induce dedifferentiation of granulosa cells and 
uncontrolled proliferation. Further loss function of p53 and BRCA1 can induce malignant 
transformation, eliciting poorly differentiated ovarian cancers. The observation that 
mesenchymal type of HGSOC is characterized with poorly differentiated phenotype 
supports our idea (118). The detailed mechanism underlying YAP regulation of granulosa 
cell reprogramming and transformation warrants further investigations. Currently, we are 
also using several mouse strains to study the tumorigenesis of granulosa cells. 
3.4.3. The genomic instability of HGSOC 
Cell reprogramming factors have potential to induce DNA damage (146). DNA damage 
response pathways might be a potential link between somatic cell dedifferentiation and 
tumorigenesis. p53 plays critical role in the cellular DNA damage response process to 
87 
protect cells from potential inherited chromosomal aberrations during the process of 
dedifferentiation. Abrogation of p53 leads to persistent DNA damage and chromosomal 
aberrations during cell reprogramming (146, 147). Importantly, recent studies showed that 
mutated p53 could promote tumor progression via gain-of-function, further supporting the 
importance of p53 in the development of HGSOC (148-150). Similarly, BRCA1/2 are also 
critical for maintaining genome stability (151, 152). Unfortunately, TP53 is mutated in the 
majority of patients with HGSOC (128). Abnormal inactivation of BRCA1/2 genes is 
considered to contribute to the development of more than half of HGSOC (110). Genome 
instability is one of the most important genetic features of HGSOC (128, 135). In the 
present study, we found that YAP overactivation was able to induce malignant ovarian 
tumors from poorly differentiated granulosa cells with genome instability, which is 
supported by recently studies showing genome instability induced by YAP (153, 154). 
Combined YAP overactivation with alternations of TP53 and BRCA1 genes, two notorious 
susceptibility genes in HGSOC, tumor progression was significantly promoted. More 
importantly, tumor cells shown severe genome instability, mimicking the genetic feature 
of human HGSOC.  Therefore, with the combination of overactive YAP oncoprotein and 
inactivation of tumor suppressors p53 and/or BRCA1, poorly differentiated granulosa cells 
can be vulnerable for malignant transformation, leading to the development of 
mesenchymal type of HGSOC. 
3.4.4. Clinical significance 
Our findings have significant clinical relevance. Tumor heterogeneity in histology and 
genome has been blamed, in part, for the poor prognosis of the HGSOC. Understanding 
on the cell-of-origin of different subtype of HGSOC and the molecular events underlying 
the initiation and progression of HGSOC should provide clues for the effective prevention, 
early diagnosis, and personalized treatment of HGSOC. In the present study, we showed 
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that disruption of the Hippo-YAP pathway may result in malignant transformation of 
ovarian poorly differentiated granulosa cells, leading to the development of HGSOC with 
mesenchymal features. Targeting the Hippo-YAP pathway may represent a novel strategy 




Figure 3-1. YAP induces non-granulosa cell tumors from poorly differentiated 
granulosa cells.  
A). Western blot showing overexpression of wild type YAP and constitutively active 
YAP
S127A
 protein in HGrC1 cells. β-Actin as control. 
B) Overexpression of YAP promotes HGrC1 cell proliferation; each point on the growth 
curves represents the mean ± SEM (n ≥ 4); when compared with control at 10 d, **: P < 
0.01, ***: P < 0.001. 
C) Representative pictures and quantitative data showing the size of spheroids formed by 
HGrC1-MX, HGrC1-YAP, and HGrC1-YAPS127A cells in the 3D culture system after 
loading for 5 d; scale bar: 200 μm; each bar represents the mean ± SEM (n ≥ 4); bars with 
different letters are significantly different from each other (P < 0.05).  
D) Representative images and quantitative data showing colony formation by HGrC1-MX, 
HGrC1-YAP, and HGrC1-YAPS127A cells; scale bar: 500 μm; each bar represents the 
mean ± SEM (n ≥ 4); bars with different letters are significantly different from each other 
(P < 0.05).  
E) Representative pictures show tumor formation by HGrC1-YAP and HGrC1-YAPS127A 
but not HGrC1-MX cells using xenograft mouse models.   
F) Tumor growth indicated by increasing volume of tumors; each point on the growth 
curves represents the mean ± SEM (n = 10); when compared with control at the end point, 
***: P < 0.001. 
G) Bar graph showing tumor weight; each bar represents the mean ± SEM (n = 10); bars 
with different letters are significantly different from each other (P < 0.05).  
H) Representative picture showing hematoxylin and Eosin stain (H & E) of tumor tissues; 
scale bar: 50 μm. 
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I) Representative images showing the expression of Ki67, aromatase, and YAP in tumor 





Figure 3-2. YAP induces malignant ovarian cancers from poorly differentiated 
granulosa cells. 
A) Representative images showing colonies formed by HGrC1-CTL, HGrC1-p53R175H, 
HGrC1-YAPS127A, HGrC1-YAPS127Ap53R175H, and HGrC1-YAPS127Ap53R175HBRCA1-/- cells; 
scale bar: 500 μm; right graph showing quantitative data of colony numbers; each bar 
represents the mean ± SEM (n ≥ 6); ns: no significance, **: P <0.01, ***: P < 0.001.  
B) Representative images show that ascites presents and malignant ovarian cancer 
spreads in the mouse abdomen, including peritoneum, mesentery, diaphragm, pancreas, 
and liver, in the host mice intraperitoneally injected with HGrC1-YAPS127A, HGrC1-
YAPS127Ap53R175H, and HGrC1-YAPS127Ap53R175HBRCA1-/- cells; the same color of arrows 
and organ/tissue names are matched. 
C) Representative images showing the histology of the malignant ovarian cancers 
metastasized to multiple organs/tissues; scale bar: 50 μm. 
D) Survival data of host mice injected with HGrC1-CTL, HGrC1-p53R175H, HGrC1-YAPS127A, 





Figure 3-3. YAP elicits HGSOC-like tumors from poorly differentiated granulosa 
cells. 
A) Representative images showing expression of Ki-67, WT-1, PAX8, Myc, Keratin 7 
(KRT7), YAP, and N-Cadherin protein in tumor tissues analyzed by immunohistochemistry; 
scale bar: 50 μm. 
B) Representative images showing that tumor tissues are negative for the expression of 
aromatase, inhibin, Keratin 20 (KRT20), PAX2, E-Cadherin, and CA125; scale bar: 50 μm. 
C) Representative picture showing tumor tissues are negative for PAS stain; scale bar: 50 
μm.  
D) Representative images showing nuclear p53 expression in tumors derived from 
HGrC1-YAPS127Ap53R175H and HGrC1-YAPS127Ap53R175HBRCA1-/- cells, but not in tumors 






Figure 3-4. YAP induces HGSOC-like tumors with mesenchymal feature from poorly 
differentiated granulosa cells. 
Western blot analyses showing the expression of WT1, PAX8, Myc, Keratin 7 (KRT7), N-
Cadherin, E-Cadherin, vimentin, p53, YAP, and BRCA1 in cell lines and tumor cells. 




Figure 3-5. Tumors derived from poorly differentiated granulosa cells genetically 
resemble HGSOC.  
Tumors derived from granulosa cells exhibits genomic instability as women’s HGSOC. 
aCGH analysis results showing DNA copy number changes of tumors formed by HGrC1-
YAPS127A, HGrC1-YAPS127Ap53R175H, and HGrC1-YAPS127Ap53R175HBRCA1-/- cells, as well 
as control cells (HGrC1-CTL). The y axis represents gain (positive, blue) or loss (negative, 
red) of copy number, while the x axis represents each chromosome. Tumors from HGrC1-





Table 1. Primers for PCR. 
Gene Name Primers 
Human  
HBEGF F: GCTCCCTCCTGCATCTGCCA 
 R: GAGGCTCAGCCCATGACACCTCT 
CYP19A1 F: TGAATATTGGAAGGATGCACAGAC 
 R: TGGAATCGTCTCAGAAGTGTAACGAG 
CYP11A1 F: TGGGTCGCCTATCACCAGTAT  
 R: CCACCCGGTCTTTCTTCCA 
FSHR F: TTCAAGAACAAGGATCCATTCC 
 R: CCTGGCCCTCAGCTTCTTAA 
LHCGR F: TCAATGTGGTGGCCTTCTTCATA 
 R: TTGGCACAAGAATTGATGGGATA 
INHA F: GTCTCCCAAGCCATCCTTTT 
 R: TGGCAGCTGACTTGTCCTC 
INHBB F: ATCAGCTTCGCCGAGACA 
 R: GCCTTCGTTGGAGATGAAGA 
INHBA F: CTCGGAGATCATCACCGTTTG 
 R: CCTTGGAAATCTCGAAGTGC 
PLIN2 F: TCAGCTCCATTCTACTGTTCACC 
 R: CCTGAATTTTCTGATTGGCACT 
MYC F: CCTACCCTCTCAACGAC 
 R: ATCTTCTTGTTCCTCCTCAG 
TERT F: GCCTGAGCTGTACTTTGTCAA 
 R: CGCAAACAGCTTGTTCTCCATGTC 
YAP F: GCAACTCCAACCAGCAGCAACA 
 R: CGCAGCCTCTCCTTCTCCATCTG 
CTGF F: ACCTGTGGGATGGGCATCT 
 R: CAGGCGGCTCTGCTTCTCTA 
AREG F: TGGAAGCAGTAACATGCAAATGTC 
101 
 R: GGCTGCTAATGCAATTTTTGATAA 
GAPDH F: CAGCCTCAAGATCATCAGCA 
R: GTCTTCTGGGTGGCAGTGAT 
Mouse  
Hsd3b1 F: ACTGCAGGAGGTCAGAGCT 
 R: GCCAGTAACACACAGAATACC 
Hbegf F: ATGAAGCTGCTGCCGTCGGT 
 R: TCAGTGGGAGCTAGCCACGC 
Ctgf F: CCCGCCAACCGCAAGATT 
 R: AGGCGGCTCTGCTTCTCCA 
Areg F: AATGAGAACTCCGCTGCTAC 
 R: CCCCTGTGGAGAGTTCACTG 
Yap F: CCCGACTCCTTCTTCAAGC 
 R: CTCGAACATGCTGTGGAGTC 
Gapdh F: CCCTTCATTGACCTCAACTA 














Table 2. Antibodies 
Antibody Vendor 
YAP 
Cell Signaling (Danvers, MA, USA) 
Phospho YAP 
Cell Signaling (Danvers, MA, USA) 
LATS1 
Cell Signaling (Danvers, MA, USA) 
Phospho LATS1 
Cell Signaling (Danvers, MA, USA) 
LATS2 
Cell Signaling (Danvers, MA, USA) 
Phospho ERK1/2 
Cell Signaling (Danvers, MA, USA) 
Phospho CREB 
Cell Signaling (Danvers, MA, USA) 
Phospho AKT 
Cell Signaling (Danvers, MA, USA) 
Cleaved Caspase 3 
Cell Signaling (Danvers, MA, USA) 
Vimentin 
Cell Signaling (Danvers, MA, USA) 
Snail 
Cell Signaling (Danvers, MA, USA) 
Slug 
Cell Signaling (Danvers, MA, USA) 
ZO-1 
Cell Signaling (Danvers, MA, USA) 
Erbb3 
Cell Signaling (Danvers, MA, USA) 
E-cadherin 
Cell Signaling (Danvers, MA, USA) 
N-cadherin (WB) 
Cell Signaling (Danvers, MA, USA) 
N-cadherin (IHC) 
Abcam (Cambridge, MA, USA) 
Myc (WB) 
Cell Signaling (Danvers, MA, USA) 
Myc (IHC) 
Abcam (Cambridge, MA, USA) 
Aromatase (rabbit, IHC) 
Cell Signaling (Danvers, MA, USA) 
Aromatase (mouse, WB) 
Bio-Rad (Hercules, CA, USA) 
3β-HSD 
Ian Mason, Ph.D. (Dallas, TX, USA) 
P450scc 
Millipore (Danvers, MA, USA) 
p53 (rabbit, IHC) 
Santa Cruz (Dallas, TX, USA) 
p53 (mouse, IF, WB) 
Agilent Technologies (Santa Clara, CA, USA) 
BRCA1 
Santa Cruz (Dallas, TX, USA) 
103 
Keratin 20 
Cell Signaling (Danvers, MA, USA) 
PAX8 
Proteintech (Rosemont, IL, USA) 
PAX2 
Proteintech (Rosemont, IL, USA) 
WT1 
Cell Signaling (Danvers, MA, USA) 
Inhibin beta A 
Abcam (Cambridge, MA, USA) 
CA125 
Abcam (Cambridge, MA, USA) 
KI67 
Abcam (Cambridge, MA, USA) 
β-Actin 
Sigma-Aldrich (St. Louis, MO, USA) 
β-Tubulin 
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